<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004449.pub4" GROUP_ID="CF" ID="748303051316105715" MERGED_FROM="" MODIFIED="2015-10-29 10:59:46 +0000" MODIFIED_BY="Tracey Remmington" REVIEW_NO="0057" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2015-10-29 10:58:11 +0000" MODIFIED_BY="Tracey Remmington">
<TITLE MODIFIED="2015-06-04 10:43:11 +0100" MODIFIED_BY="Tracey Remmington">Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors</TITLE>
<CONTACT>
<PERSON ID="11708" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alfonso</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Iorio</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>iorioa@mcmaster.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+12893393713</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1>1280 Main Street West</ADDRESS_1>
<ADDRESS_2>CRL - 140</ADDRESS_2>
<CITY>Hamilton</CITY>
<ZIP>L8S 4K1</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 905 525 9140 ext 22421</PHONE_1>
<PHONE_2>+1 289 339 3713</PHONE_2>
<FAX_1>+1 905-526-8447</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-10-29 10:58:11 +0000" MODIFIED_BY="Tracey Remmington">
<PERSON ID="EC68B36D82E26AA20190533520A7B2C5" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Davide</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Matino</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>davide.matino@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>University of Perugia</ORGANISATION>
<ADDRESS_1>Ospedale Santa Maria della Misericordia</ADDRESS_1>
<ADDRESS_2>Località Sant'Andrea delle Fratte</ADDRESS_2>
<CITY>Perugia</CITY>
<ZIP>06126</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 075 578 2309</PHONE_1>
<PHONE_2/>
<FAX_1>+39 075 578 2309</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12129" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Makris</LAST_NAME>
<SUFFIX/>
<POSITION>Reader in Haematology and Honorary Consultant Haematologist</POSITION>
<EMAIL_1>m.makris@sheffield.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL>http://www.shef.ac.uk/dgm/gi/auh/people/mm.html</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Academic Unit of Haematology</DEPARTMENT>
<ORGANISATION>University of Sheffield</ORGANISATION>
<ADDRESS_1>H Floor</ADDRESS_1>
<ADDRESS_2>Royal Hallamshire Hospital</ADDRESS_2>
<CITY>Sheffield</CITY>
<ZIP>S10 2JF</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 114 271 2760</PHONE_1>
<PHONE_2/>
<FAX_1>+44 114 275 6126</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B8C5F2D582E26AA2007D5B6E64A17F87" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kerry</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Dwan</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Statistician</POSITION>
<EMAIL_1>Kerry.Dwan@liverpool.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL>http://smg.cochrane.org/</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Biostatistics</DEPARTMENT>
<ORGANISATION>University of Liverpool</ORGANISATION>
<ADDRESS_1>Alder Hey Children's NHS Foundation Trust</ADDRESS_1>
<ADDRESS_2>Eaton Road</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L12 2AP</ZIP>
<REGION>England</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 252 5696</PHONE_1>
<PHONE_2/>
<FAX_1>+44 151 252 5496</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11485" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Roberto</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>D'Amico</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant professor</POSITION>
<EMAIL_1>roberto.damico@unimore.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+39 3316213042</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Italian Cochrane Centre, Department of Diagnostic, Clinical and Public Health Medicine</DEPARTMENT>
<ORGANISATION>University of Modena and Reggio Emilia</ORGANISATION>
<ADDRESS_1>Via del Pozzo 71</ADDRESS_1>
<ADDRESS_2/>
<CITY>Modena</CITY>
<ZIP>41124</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 059 4223865</PHONE_1>
<PHONE_2/>
<FAX_1>+39 059 4223235</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11708" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alfonso</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Iorio</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>iorioa@mcmaster.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+12893393713</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1>1280 Main Street West</ADDRESS_1>
<ADDRESS_2>CRL - 140</ADDRESS_2>
<CITY>Hamilton</CITY>
<ZIP>L8S 4K1</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 905 525 9140 ext 22421</PHONE_1>
<PHONE_2>+1 289 339 3713</PHONE_2>
<FAX_1>+1 905-526-8447</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-10-16 10:27:42 +0100" MODIFIED_BY="Tracey Remmington">
<UP_TO_DATE>
<DATE DAY="16" MONTH="10" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="9" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="10" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-10-19 11:26:27 +0100" MODIFIED_BY="Tracey Remmington">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-10-19 11:26:27 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="16" MONTH="10" YEAR="2015"/>
<DESCRIPTION>
<P>While no new trials have been included in the update, after receiving additional data from trial authors, the two included (cross-over) trials were re-analyzed using the marginal probabilities method (<LINK REF="REF-Becker-1993" TYPE="REFERENCE">Becker 1993</LINK>; <LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-10-16 10:27:51 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="16" MONTH="10" YEAR="2015"/>
<DESCRIPTION>
<P>Literature searches were performed and the manuscript was updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-09-17 11:38:45 +0100" MODIFIED_BY="Tracey Remmington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-07-18 15:28:21 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="15" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-02-15 13:45:18 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="7" MONTH="7" YEAR="2010"/>
<DESCRIPTION>
<P>The search of the Group's Coagulopathies Trials Register identified six references to five new trials; two trials have been included (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>; <LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>) and the remaining three trials have been excluded (<LINK REF="STD-Kavakli-2006" TYPE="STUDY">Kavakli 2006</LINK>; <LINK REF="STD-Pruthi-2007" TYPE="STUDY">Pruthi 2007</LINK>; <LINK REF="STD-Santagostino-2006" TYPE="STUDY">Santagostino 2006</LINK>).</P>
<P>The review protocol was modified to include people with both haemophilia A and haemophilia B. No difference exists in the treatment of individuals with inhibitors in each of the two conditions. We therefore see no reason to limit the review to individuals with haemophilia A, even if most of the people with inhibitors are haemophilia A patients (inhibitor occurrence in haemophilia B is much more rare).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-02-15 13:45:18 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="7" MONTH="7" YEAR="2010"/>
<DESCRIPTION>
<P>A new review team has taken on this review and updated it including two new trials where previously none were included.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-07-02 07:57:30 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="14" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-07-02 08:03:20 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="15" MONTH="2" YEAR="2006"/>
<DESCRIPTION>
<P>The search of the Group's Coagulopathies Trials Register identified one reference (Villar 2004), this has now been listed under 'Excluded studies'.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-07-02 08:04:16 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="11" MONTH="2" YEAR="2005"/>
<DESCRIPTION>
<P>The search of the Group's Coagulopathies Trials Register identified one trial, but this was not eligible for inclusion in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="24" MONTH="2" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-10-19 12:29:35 +0100" MODIFIED_BY="Tracey Remmington">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-10-19 12:29:35 +0100" MODIFIED_BY="Tracey Remmington">
<SOURCE MODIFIED="2015-10-19 12:29:22 +0100" MODIFIED_BY="Tracey Remmington">
<NAME>National Institute for Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-10-19 13:03:36 +0100" MODIFIED_BY="Tracey Remmington">
<SUMMARY MODIFIED="2015-10-19 13:03:36 +0100" MODIFIED_BY="Tracey Remmington">
<TITLE MODIFIED="2015-10-19 13:03:36 +0100" MODIFIED_BY="Tracey Remmington">Recombinant (non-human) factor VIIa clotting factor concentrates versus plasma concentrates for acute bleeds in people with haemophilia and inhibitors</TITLE>
<SUMMARY_BODY MODIFIED="2015-10-19 11:48:57 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<BR/>
<B>Review question</B>
</P>
<P>We wanted to find evidence on the effectiveness of recombinant factor VIIa (containing no human proteins) as compared to concentrates derived from plasma for treating acute bleeding episodes in people with haemophilia with inhibitors.</P>
<P>
<B>Background</B>
</P>
<P>Haemophilia is an inherited bleeding disorder caused by a lack of a clotting factor and is characterised by bleeding into the joints. It is treated by injecting a drug containing the missing clotting factor into veins. In some individuals with haemophilia, this factor is seen by the body as a foreign protein when it is injected and the body produces an antibody (inhibitor) that destroys the factor. In this way these people become resistant to treatment. Once someone with haemophilia develops an inhibitor, they are treated to remove the antibody (immunotolerance induction) and for acute bleeding episodes. Treatment for bleeding episodes is with one of two available bypassing agents, recombinant activated factor VIIa (Novoseven<SUP>®</SUP>) or human activated prothrombin complex concentrate (FEIBA<SUP>®</SUP>). It is not known if one of these products is better than the other. We searched for trials comparing the effectiveness (time until bleeding stops, effect on joint motion, need for re-treatment) and safety of Novoseven<SUP>®</SUP> and FEIBA<SUP>®</SUP> in people with haemophilia with inhibitors during episodes of acute bleeding.</P>
<P>
<B>Search date</B>
</P>
<P>The evidence is current to: 23 September 2015.</P>
<P>
<B>Study characteristics</B>
</P>
<P>The review included two trials with 69 people (aged one to 55 years) with severe haemophilia with inhibitors<I>. </I>Both trials compared recombinant factor VIIa with activated prothrombin complex concentrate and people were selected for one treatment or the other randomly.</P>
<P>
<B>Key results</B>
<BR/>We found two clinical trials comparing Novoseven<SUP>®</SUP> and FEIBA<SUP>®</SUP>. The trials did not show a difference in how well the two products worked and both were tolerated equally well with no clotting complications. We conclude that both recombinant factor VIIa and plasma-derived concentrates can be used to treat bleeds in people with haemophilia and inhibitors.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>There were some major problems with regards to the way both trials were designed, in relation to knowing which treatment group each person was in (both before the trial was started and during) and also how missing results were handled.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-10-19 11:32:25 +0100" MODIFIED_BY="Tracey Remmington">
<ABS_BACKGROUND MODIFIED="2015-10-19 11:27:55 +0100" MODIFIED_BY="Tracey Remmington">
<P>In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and induce anti-factor VIII antibodies, known as 'inhibitors'. Drugs insensitive to such antibodies, either recombinant or plasma-derived, are called factor VIII 'by-passing' agents and used for treatment of bleeding in people with inhibitors.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-10-19 11:28:00 +0100" MODIFIED_BY="Tracey Remmington">
<P>To determine the clinical effectiveness of recombinant factor VIIa concentrate compared to plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-10-16 10:28:17 +0100" MODIFIED_BY="Tracey Remmington">
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Coagulopathies Trials Register which comprises references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.</P>
<P>Date of the most recent search of the Group's Coagulopathies Trials Register: 23 September 2015.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-10-19 11:29:06 +0100" MODIFIED_BY="Tracey Remmington">
<P>Randomised and quasi-randomised controlled clinical trials comparing recombinant factor VIIa concentrate to human plasma-derived concentrates (high-dose human or recombinant factor VIII or factor IX concentrate; non-activated prothrombin complex concentrates; activated prothrombin complex concentrates) in people with haemophilia. Comparisons with animal-derived products were excluded.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-10-19 11:30:46 +0100" MODIFIED_BY="Tracey Remmington">
<P>Two authors independently assessed the trials (eligibility and risk of bias) and extracted data. No combined meta-analyses were performed due to the unavailability of outcomes and comparisons common to the included trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-10-19 11:31:25 +0100" MODIFIED_BY="Tracey Remmington">
<P>A total of 15 trials were identified, two of which (with data for a total of 69 participants) were eligible for analysis. Both trials showed methodological flaws and did not show superiority of one treatment over the other. Both the treatments showed that recombinant factor VIIa and activated prothrombin complex concentrate appeared to have a similar haemostatic effect in both trials, without increasing thromboembolic risk.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-10-19 11:32:25 +0100" MODIFIED_BY="Tracey Remmington">
<P>Based on the separate analysis of the two available randomised trials, recombinant factor VIIa and activated prothrombin complex concentrate were found to be similar in efficacy and safety. However, there is a need for further, well-designed, adequately-powered, randomised controlled trials to assess the relative benefits and risks of using recombinant factor VIIa compared to human plasma-derived concentrates in people with haemophilia with inhibitors. It is advisable that researchers in the field define commonly agreed objective outcome measures in order to enable the pooling of their results, thus increasing the power of comparisons. To date, data could not be combined in a formal meta-analysis. For the same reason reporting concordant and discordant pairs in cross-over trials is recommended.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-10-19 12:33:01 +0100" MODIFIED_BY="Tracey Remmington">
<BACKGROUND MODIFIED="2015-10-19 11:54:06 +0100" MODIFIED_BY="Tracey Remmington">
<CONDITION MODIFIED="2015-10-19 11:50:34 +0100" MODIFIED_BY="Tracey Remmington">
<P>Haemophilia is an inherited disorder where affected individuals suffer from excessive bleeding. It is inherited as an X-linked disorder, but in around a third of all cases no family history is present. People with haemophilia develop spontaneous bleeding into joints and suffer excessive bleeding after injury or surgery which can be hazardous unless appropriately managed in expert centres. Two main types are recognised due to either a deficiency of factor VIII (FVIII) (haemophilia A) or of factor IX (FIX) (haemophilia B). The prevalence is similar worldwide and for haemophilia A is 1 in 10,000 and for haemophilia B is 1 in 60,000 births (<LINK REF="REF-Mannucci-2001" TYPE="REFERENCE">Mannucci 2001</LINK>).</P>
<P>The severity of the phenotype depends on the baseline concentration of the clotting factor. The severity of haemophilia has been defined by the International Society for Thrombosis and Haemostasis as:</P>
<UL>
<LI>severe, where the factor is less than 0.01 units per millilitre (u/ml);</LI>
<LI>moderate, where the factor ranges from 0.01 u/ml to less than 0.05 u/ml; and</LI>
<LI>mild, where the factor is greater than 0.05 u/ml (<LINK REF="REF-White-2001" TYPE="REFERENCE">White 2001</LINK>).</LI>
</UL>
<P>Spontaneous bleeding into joints is seen primarily in people with severe haemophilia.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-08-20 15:16:33 +0100" MODIFIED_BY="Tracey Remmington">
<P>The mainstay of treatment in bleeding disorders due to factor deficiency is the correction of the defect by the intravenous infusion of the appropriate clotting factor. For haemophilia, initially in the 1960s this consisted of the infusion of fresh frozen plasma (haemophilia A and haemophilia B) and cryoprecipitate (haemophilia A) and was followed in the 1970s by the introduction of FVIII (haemophilia A) or FIX (haemophilia B) concentrates. Over the last 30 years the purity of concentrates has increased; and since 1985 viral inactivation procedures were introduced to eliminated blood product-transmitted infections such as HIV and hepatitis C (<LINK REF="REF-Rizza-2001" TYPE="REFERENCE">Rizza 2001</LINK>). At the beginning of the 1990s recombinant factor concentrates (that do not contain human proteins) were developed and these have entered clinical practice (<LINK REF="REF-UKHCDO-2003" TYPE="REFERENCE">UKHCDO 2003</LINK>).</P>
<P>In some people with haemophilia the administered factor is recognised as a foreign protein and anti-FVIII or anti-FIX antibodies are produced. These antibodies are referred to as inhibitors when they inhibit the activity of the administrated factor. The reported prevalence of inhibitors in haemophilia A varies enormously from 3.6% (<LINK REF="REF-Yee-1999" TYPE="REFERENCE">Yee 1999</LINK>) to 32% (<LINK REF="REF-Kreuz-2002" TYPE="REFERENCE">Kreuz 2002</LINK>). The incident rate of inhibitors is much lower in haemophilia B than in haemophilia A, but inhibitor treatment in haemophilia B is hampered by complications due to immuno-complex mediated renal damage (<LINK REF="REF-Ewenstein-1997" TYPE="REFERENCE">Ewenstein 1997</LINK>). The risk of developing an inhibitor has been found to be associated with: the causative genetic defect (<LINK REF="REF-Dimichele-2002" TYPE="REFERENCE">Dimichele 2002</LINK>), with gene deletions having the highest risk of developing an inhibitor (<LINK REF="REF-Goodeve-2003" TYPE="REFERENCE">Goodeve 2003</LINK>); ethnicity; family history of haemophilia with or without inhibitors; the length and intensity of exposure to factor concentrates; the age at first exposure; and the occurrence of a trigger event (i.e. bleeding, surgery or infections). Other reasons for the varying prevalence of inhibitors observed in different published reports may be the laboratory method for measuring the inhibitor as well as the frequency of inhibitor testing. The lower prevalence of gene deletions in haemophilia B partly explains the lower rate of inhibitor development (<LINK REF="REF-DiMichele-2007" TYPE="REFERENCE">DiMichele 2007</LINK>).</P>
<P>There are two key elements in the treatment of people with haemophilia with inhibitors. The first, which is addressed by this review, is the treatment of the individual to arrest the acute bleeding. The second element is treatment to eliminate the inhibitor (immune tolerance induction), which is the subject of another Cochrane review (<LINK REF="REF-Athale-2014" TYPE="REFERENCE">Athale 2014</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2015-10-19 11:54:06 +0100" MODIFIED_BY="Tracey Remmington">
<P>The acute treatment of someone with haemophilia and an inhibitor depends on the level of the antibody or inhibitor that is measured <I>in vitro</I> and is quantified in Bethesda units. A Bethesda unit is a measure of inhibitor activity and is the amount of inhibitor that will inactivate 50% or 0.5 unit of a coagulation factor in an activated partial thromboplastin time (aPTT)-based coagulation factor assay following a two-hour incubation period in an imidazole buffer diluted sample. Although some people with haemophilia with low levels of inhibitor can be treated with standard concentrates, in practice most have inhibitors that destroy the infused FVIII or FIX and other products have been developed to treat these individuals. These are based on human plasma such as activated prothrombin complex concentrates (aPCC) (brands available are FEIBA<SUP>®</SUP> and Autoplex<SUP>®</SUP>) or non-activated prothrombin complex concentrates (PCC) or animal plasma such as Hyate-C<SUP>®</SUP> (FVIII prepared from porcine plasma, can be used in people with haemophilia with no antibodies to porcine FVIII) (<LINK REF="REF-Hay-2000" TYPE="REFERENCE">Hay 2000</LINK>). A more recent alternative approach has been the use of recombinant FVIIa concentrate (rFVIIa) (NovoSeven<SUP>®</SUP>), which was introduced early in the 1990s and shown to be highly effective but also associated with a relatively high cost (<LINK REF="REF-Hedner-2000" TYPE="REFERENCE">Hedner 2000</LINK>). Mainly aPCC exerts its effect by providing activated factor IX and X, which are able to produce a significant amount of thrombin without any requirement for FVIII (<LINK REF="REF-Thomas-1977" TYPE="REFERENCE">Thomas 1977</LINK>); noticeably, aPCC is not expected to be active in people with factor IX deficiency. At a pharmacological concentration, rFVII is able to directly activate thrombin when bound to tissue factor or to activate factor Xa on the surface of activated platelets (<LINK REF="REF-Hedner-2000" TYPE="REFERENCE">Hedner 2000</LINK>). The difference in the mechanism of action of the two compounds makes it reasonable to switch the non-responding individual from one treatment to the other, and to assess the efficacy and safety of the combination of the two drugs.</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-07-07 12:13:33 +0100" MODIFIED_BY="[Empty name]">
<P>This review investigates which is the most effective treatment of acute bleeding in people with haemophilia with inhibitors.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-10-19 11:52:21 +0100" MODIFIED_BY="Tracey Remmington">
<P>To determine the clinical effectiveness of rFVIIa in comparison to PCC or aPCC for treating acute bleeding episodes in people with haemophilia with inhibitors.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-10-19 12:33:01 +0100" MODIFIED_BY="Tracey Remmington">
<SELECTION_CRITERIA MODIFIED="2015-10-19 12:33:01 +0100" MODIFIED_BY="Tracey Remmington">
<CRIT_STUDIES>
<P>Randomised (RCTs) and quasi-randomised controlled clinical trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-05-01 13:32:22 +0100" MODIFIED_BY="[Empty name]">
<P>Children and adults with haemophilia, of all degrees of severity diagnosed by decreased blood levels of functional procoagulant FVIII or FIX and with FVIII or FIX inhibitors of any titre.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-03-25 16:16:46 +0000" MODIFIED_BY="[Empty name]">
<P>Recombinant FVIIa concentrate (rFVIIa) compared to human plasma-derived concentrates (high-dose human or recombinant FVIII or FIX concentrate; PCCs; aPCC). Comparisons with animal-derived products were excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-10-19 12:33:01 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-10-19 12:33:01 +0100" MODIFIED_BY="Tracey Remmington">
<OL>
<LI>Early cessation of bleeding measured by</LI>
<OL>
<LI>changes on any subjective or objective pain and mobility scale or</LI>
<LI>by the volume of haematoma assessed radiologically at any point in the first 48 hours</LI>
</OL>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-07-02 09:11:19 +0100" MODIFIED_BY="Nikki Jahnke">
<OL>
<LI>Number of participants requiring additional or alternative treatment</LI>
<LI>Number of participants with adverse effects (thromboses; allergic reactions)</LI>
<LI>Correction of abnormal haemostatic laboratory test results</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-10-16 10:28:43 +0100" MODIFIED_BY="Tracey Remmington">
<P>No restrictions based on dates, language or publication status were imposed.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-10-16 10:28:43 +0100" MODIFIED_BY="Tracey Remmington">
<P>Relevant trials were searched for on the Group's Coagulopathies Trials Register using the terms: (haemophilia A AND factor VIIa) OR (haemophilia B AND factor VIIa) OR (haemophilia general AND (recombinant factor VIIa OR factor VIIa))</P>
<P>The coagulopathies register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of <I>The Cochrane Library</I>), weekly searches of MEDLINE and the prospective handsearching of one journal - <I>Haemophilia</I>. Unpublished work is identified by searching the abstract books of four major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; and the Congress of the World Federation of Haemophilia. For full details of all searching activities for the register, please see the relevant section of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html">Cochrane Cystic Fibrosis and Genetic Disorders Group Module</A>.</P>
<P>Date of the most recent search of the Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register: 23 September 2015.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-10-19 11:58:53 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY_SELECTION MODIFIED="2015-05-01 13:36:47 +0100" MODIFIED_BY="[Empty name]">
<P>In the 2010 update, two trials were found to be eligible for inclusion (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>; <LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). Additional data were obtained from trial authors for the 2015 update and included in the review (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>; <LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>).</P>
<P>For the references found when updating the review after October 2007, two authors (AI, DM) independently selected the trials to be included in the review. When disagreement arose on the suitability of a trial for inclusion in the review or on its quality, we attempted to reach a consensus by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-07-07 12:15:45 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (AI, DM) independently extracted data using standard data acquisition forms. When disagreement arose on the suitability of a trial for inclusion in the review or on its quality, we reached a consensus by discussion.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-03-25 16:18:16 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (AI, DM) assessed the risk of bias of each trial. In particular, they examined details of the randomisation method, whether the trial was blinded, whether intention-to-treat analyses were possible from the available data and if the number of participants lost to follow up or subsequently excluded from the study was recorded. When disagreement arose on the suitability of a trial for inclusion in the review or on its quality, we reached a consensus by discussion.</P>
<SUBSECTION>
<HEADING LEVEL="4">Randomisation method</HEADING>
<P>We assessed the risk of bias from the randomisation sequence as low if this was generated using, e.g. a computer or a random numbers table; we assessed the risk of bias as unclear if the methods were not described; and we assessed the risk of bias as high if a non-random approach was used, e.g. date of birth, clinical record number.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Concealment of allocation</HEADING>
<P>We assessed the risk of bias from concealment of allocation as low if neither the participants or trial investigators could foresee the allocation of the participants (e.g. using sealed opaque envelopes); we assessed the risk of bias as unclear if methods were not described; and we assessed the risk of bias as high if alternation or an open allocation schedule was used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<P>We assessed the risk of bias from blinding as low if participants, investigators and outcome assessors were blinded (or if any of these were not blinded but outcome assessment was blinded and this was judged not to influence the outcome); we judged the risk of bias as unclear if this issue was not discussed; and we judged the risk of bias to be high if none of the parties involved in the trial were blinded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<P>We judged the risk of bias to be low if any withdrawals were described in full and were equal across groups; we judged the risk of bias to be unclear if insufficient information was given; and we judged the risk of bias to be high if the missing data were likely to be directly related to the outcome or if they were uneven across groups.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-05-01 13:46:56 +0100" MODIFIED_BY="[Empty name]">
<P>For binary outcome measures, we sought data on the number of participants with each outcome event, by allocated treated group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow-up. We aimed to calculate a pooled estimate of the treatment effect for each outcome across studies using the odds ratio (OR) (the odds of an outcome among treatment allocated participants to the corresponding odds among controls).</P>
<P>For continuous outcomes, we recorded either mean change from baseline for each group or mean post-treatment or intervention values and standard deviation (SD) for each group. Then, where appropriate, we planned to calculate a pooled estimate of treatment effect by calculating the mean difference (MD). If different scales had been used for the same outcome we would have considered using the standardised mean difference (SMD).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-05-05 13:32:28 +0100" MODIFIED_BY="[Empty name]">
<P>As we expected to find cross-over trials, we decided to analyse cross-over trials with the marginal probabilities of success method, as described by Elbourne, (<LINK REF="REF-Becker-1993" TYPE="REFERENCE">Becker 1993</LINK>; <LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>) rather than examining them as a parallel trial. Analysing cross-over trials in this way has been reported to avoid the problem of losing the advantage arising from cross-over trials (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-10-19 11:58:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>We sought the necessary data from the original investigators if reports were incomplete. This refers particularly to the data needed to apply the marginal probabilities method to cross-over trials (<LINK REF="REF-Becker-1993" TYPE="REFERENCE">Becker 1993</LINK>; <LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-10-19 11:58:53 +0100" MODIFIED_BY="Tracey Remmington">
<P>We planned to test heterogeneity between trial results using a standard Chi<SUP>2</SUP> test and the I<SUP>2</SUP> statistic using the following cut-off values (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>):</P>
<UL>
<LI>not important heterogeneity: 0% to 40%;</LI>
<LI>moderate heterogeneity: 30% to 60%;</LI>
<LI>substantial heterogeneity: 50% to 90%;</LI>
<LI>considerable heterogeneity: 75% to 100%.</LI>
</UL>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-09-28 16:14:23 +0100" MODIFIED_BY="Alfonso Iorio">
<P>We planned to assess publication bias by visual inspection of the funnel plot, and to investigate outcome reporting bias by comparing trial protocols and results from final papers, or (if protocols are not available) the methods and results sections of final papers.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-01-26 09:27:33 +0000" MODIFIED_BY="Nikki Jahnke">
<P>For the meta-analysis we planned to use a fixed-effect model unless we found moderate or significant heterogeneity, in which case we planned to use a random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-01-26 09:27:51 +0000" MODIFIED_BY="Nikki Jahnke">
<P>If we had identified moderate or significant heterogeneity, we planned to investigate this by subgroup analysis based on the level of the inhibitor (<LINK REF="REF-Hay-2000" TYPE="REFERENCE">Hay 2000</LINK>):</P>
<OL>
<LI>levels of 5 Bethesda units per millilitre (BU/ml) or less;</LI>
<LI>levels in excess of 5 BU/ml.</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-06-04 13:15:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>We planned to perform a sensitivity analysis based on the generation of the allocation sequence within the trials, including and excluding quasi-randomised trials.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-10-19 12:19:36 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY_DESCRIPTION MODIFIED="2015-10-19 12:02:18 +0100" MODIFIED_BY="Tracey Remmington">
<SEARCH_RESULTS MODIFIED="2015-06-04 10:06:19 +0100" MODIFIED_BY="Tracey Remmington">
<P>A total of 15 studies were identified by the searches (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>; <LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>; <LINK REF="STD-Chuansumrit-2000" TYPE="STUDY">Chuansumrit 2000</LINK>; <LINK REF="STD-de-Paula-2012" TYPE="STUDY">de Paula 2012</LINK>; <LINK REF="STD-Kavakli-2006" TYPE="STUDY">Kavakli 2006</LINK>; <LINK REF="STD-Ljung-2013" TYPE="STUDY">Ljung 2013</LINK>; <LINK REF="STD-Lusher-1998" TYPE="STUDY">Lusher 1998</LINK>; <LINK REF="STD-Mahlangu-2012" TYPE="STUDY">Mahlangu 2012</LINK>; <LINK REF="STD-NCT00108758" TYPE="STUDY">NCT00108758</LINK>; <LINK REF="STD-NCT01561391" TYPE="STUDY">NCT01561391</LINK>; <LINK REF="STD-Pruthi-2007" TYPE="STUDY">Pruthi 2007</LINK>; <LINK REF="STD-Santagostino-2006" TYPE="STUDY">Santagostino 2006</LINK>; <LINK REF="STD-Seremetis-1994" TYPE="STUDY">Seremetis 1994</LINK>; <LINK REF="STD-Shapiro-1998" TYPE="STUDY">Shapiro 1998</LINK>; <LINK REF="STD-Villar-2004" TYPE="STUDY">Villar 2004</LINK>) and two of these were eligible for inclusion in this review (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>; <LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). The reasons for excluding the 13 studies are summarized below (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). </P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-10-19 12:01:09 +0100" MODIFIED_BY="Tracey Remmington">
<SUBSECTION>
<HEADING LEVEL="4">Trial design</HEADING>
<P>Both of the included trials were multicentre cross-over RCTs. One trial had two arms (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>) and the second trial had three arms (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>)<I>. </I>For the comparison we are evaluating (rFVIIa versus aPCC) the trials were unblinded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Participants in both trials included adults and children with severe haemophilia with inhibitors (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>
<I>; </I>
<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). The Astermark trial only included participants with haemophilia A; the Young trial included participants with both haemophilia A and B and did not separately specify the numbers of each.</P>
<P>The Astermak trial enrolled 66 participants; however, 14 withdrew prior to treatment or were treated only once. Diaries for a further four participants were not completed (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>). The Young trial randomised 42 participants, with 21 completing all three treatment arms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Both the included trials compared rFVIIa with aPCC.</P>
<P>In the Young trial, rFVIIa 90 mcg/kg was given as an intravenous (IV) bolus administered at zero, three and six hours; rFVIIa 270 mcg/kg as single IV bolus (followed by two placebo infusions); and aPCC 75 IU/kg as a single IV bolus (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). Thus, participants were unblinded to the comparison between aPCC and rFVIIa, but were blinded to the dose of rFVIIa (90 mcg/kg x 3 doses versus 270 mcg/kg as a single bolus with two placebo solutions).</P>
<P>In the Astermark trial aPCC 75 to 100 IU/kg (target 85 IU/kg) was given as a single IV bolus; rFVIIa 90 to 120 mcg/kg (target 105 mcg/kg) was given as an IV bolus repeated after two hours (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>). Both treatments were administered a mean time of two hours after bleeding onset.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes measured</HEADING>
<P>In both the trials, due to the peculiarity of the clinical condition under evaluation, the outcomes were subjective in nature (participant judgement about the efficacy of the treatment, expressed as global evaluation, pain cessation, motility improvement, need for additional treatment). None of the outcomes measures used were common to both trials, and only one of them made assessments about the safety of the treatment (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). The primary and secondary outcomes of the Young trial were the secondary and primary outcomes of this review, respectively (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>)<I>.</I>
</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-10-19 12:02:18 +0100" MODIFIED_BY="Tracey Remmington">
<P>Among the excluded trials, two were not RCTs or quasi-RCTs (<LINK REF="STD-Chuansumrit-2000" TYPE="STUDY">Chuansumrit 2000</LINK>; <LINK REF="STD-Seremetis-1994" TYPE="STUDY">Seremetis 1994</LINK>), five were dose-finding trials, where the comparators were not alternative therapies (<LINK REF="STD-Lusher-1998" TYPE="STUDY">Lusher 1998</LINK>; <LINK REF="STD-Shapiro-1998" TYPE="STUDY">Shapiro 1998</LINK>; <LINK REF="STD-Villar-2004" TYPE="STUDY">Villar 2004</LINK>; <LINK REF="STD-Mahlangu-2012" TYPE="STUDY">Mahlangu 2012</LINK>; <LINK REF="STD-de-Paula-2012" TYPE="STUDY">de Paula 2012</LINK>); the remaining six were randomised comparisons of different regimens of rFVIIa given to treat bleeding (<LINK REF="STD-Kavakli-2006" TYPE="STUDY">Kavakli 2006</LINK>; <LINK REF="STD-Santagostino-2006" TYPE="STUDY">Santagostino 2006</LINK>; <LINK REF="STD-Ljung-2013" TYPE="STUDY">Ljung 2013</LINK>; <LINK REF="STD-NCT00108758" TYPE="STUDY">NCT00108758</LINK>) or as surgical prophylaxis (<LINK REF="STD-Pruthi-2007" TYPE="STUDY">Pruthi 2007</LINK>; <LINK REF="STD-NCT01561391" TYPE="STUDY">NCT01561391</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-10-19 12:16:30 +0100" MODIFIED_BY="Tracey Remmington">
<ALLOCATION MODIFIED="2015-10-19 12:09:58 +0100" MODIFIED_BY="Tracey Remmington">
<SUBSECTION>
<HEADING LEVEL="4">Generation of randomisation sequence</HEADING>
<P>In one trial randomisation in association with the first bleeding event was performed in a block of participants equally divided into two (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>). The method of randomisation for that first event is not given in the paper. In the second trial, six treatment sequences were generated by the permutation of the three dosing regimens (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). The sequences were randomly assigned to the participants. There is no further information about the method of randomisation in the paper. The risk of bias has to be considered unclear in both trials due to lack of details about randomisation sequence generation; furthermore, blocking by two allows the investigator to guess the treatment assigned to the subsequent participant (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Concealment of allocation</HEADING>
<P>Both trials were open label for the comparison of rFVIIa versus aPCC, which would mean there was sub-optimal allocation concealment. However, in the Young trial the comparison between the two different rFVIIa regimens did not provide details about randomisation code concealment. We therefore judged one trial to be at a high risk of bias (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>) and one to be at an unclear risk of bias (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2015-03-25 16:21:45 +0000" MODIFIED_BY="[Empty name]">
<P>One trial was not blinded for physicians and participants because of the major difference between the two products (physical appearance and required volume for injection); outcome assessment was also not blinded (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>). In the second trial, participants and clinicians could not be blinded to the comparison between the two rFVIIa treatments and the aPCC treatment due to differences in physical appearance and required volume for injection, but comparison between the two rFVIIa treatments was blinded (three active boluses versus one active and two placebo boluses) (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). Outcome assessment in this trial was blinded.</P>
<P>The risk of bias has to be considered high in both trials.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-10-19 12:15:20 +0100" MODIFIED_BY="Tracey Remmington">
<P>A total of 48 participants out of 66 completed the Astermark trial protocol for all time points (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>). There were 14 participants who withdrew prior to treatment or were treated only once. Reasons for withdrawal included: no bleeding episodes in the study joints or the timing of prophylactic or other infusions prevented participation (six participants); lack of compliance with the protocol (three participants); concern about using a unfamiliar product, or change of mind about participation (two participants); the trial was stopped by the Ministry of Health in one country because the products were not provided free of charge (one participant); no reason was given for the withdrawal of two participants; the diaries of four participants were not adequately completed for inclusion in the analysis. The trial was reported as to be analysed on an intention-to-treat basis, but actually appears to be analysed per protocol, we therefore assessed this trial as having a high risk of bias (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>).</P>
<P>A total of 21 participants out of 42 completed the Young trial protocol (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). Fourteen participants were randomised but not treated; of the remaining 27 participants, six were withdrawn: three of these for non-compliance; two for study closure; and one because the participant moved to another centre. The trial was prematurely interrupted and analysed per protocol and thus assessed as having a high risk of bias (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-10-19 12:16:02 +0100" MODIFIED_BY="Tracey Remmington">
<P>We were not able to compare the trial protocols and reports for either trial, due to unavailability of the protocols (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>; <LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). No discrepancy was found between the methods and results sections of the reports. The outcomes and timing were those commonly used in the field and pre-specified as outcome measures for this review. We therefore judge there to be a low risk of bias from selective reporting.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-10-19 12:16:30 +0100" MODIFIED_BY="Tracey Remmington">
<P>Only one of the trials had an objective rather than a subjective measure as the principal outcome (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>); and a risk of bias is inherent in the use of any subjective outcomes (participant-reported measures). The use of analgesics was allowed during both trials, and potentially interfered with subjective pain assessment by the participants. One trial evaluated the distribution of analgesics in the treatment groups (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>). The remaining trial tried to adjust for the concomitant use of analgesic drugs (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). A significantly different number of knee (higher in rFVIIa-treated participants) and elbow (higher in aPCC-treated participants) bleeding events were recorded in one trial and the analysis technique used to balance for the uneven distribution of knee bleeds is unfair and not sufficiently detailed (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>). The Young trial was interrupted by the sponsor for unspecified reasons (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-10-19 12:19:36 +0100" MODIFIED_BY="Tracey Remmington">
<P>We are unable to perform any formal meta-analyses because the two trials did not have any overlapping outcomes amenable for pooling; therefore, we have simply summarized the results of each of the trials. The authors of both trials provided the data needed to perform the marginal probabilities of success method, namely the number of participants in each of the following groups, for all the relevant outcomes at each reported time-point: success in both treatment phases; failure in both treatment phases; success with rFVIIa; and failure with aPCC; failure with rFVIIa; and success with aPCC. As previously described by Elbourne, analysing cross-over trials in this way has been reported to avoid the problem of losing the advantage arising from cross-over trials (<LINK REF="REF-Becker-1993" TYPE="REFERENCE">Becker 1993</LINK>; <LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). This is our primary analysis and results are reported in the forest plots (<LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>). We have also reported the outcome effect measures provided in the original trials in additional tables (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Early cessation of bleeding</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a. changes on any subjective or objective pain and mobility scale</HEADING>
<P>The primary outcome of the Astermark trial was evaluation of haemostatic effect at six hours following treatment (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>). An effective response was defined by creating a dichotomy of the effective and partially effective response versus poorly effective and not effective. Full details of the results analyzed with the marginal probabilities method (<LINK REF="REF-Becker-1993" TYPE="REFERENCE">Becker 1993</LINK>) for this outcome are presented (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). A secondary outcome of the Astermark trial, not included in our protocol, is also reported in the additional tables (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>The main outcome of the Young trial was an algorithm taking into account pain and mobility scores, and it did not find any significant difference between the treatment groups (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). This algorithm has not, as yet, been formally validated. The marginal probability score (<LINK REF="REF-Becker-1993" TYPE="REFERENCE">Becker 1993</LINK>) was recalculated separately for mobility and pain for the assessments at one, three, six and nine hours (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). The number of participants requiring analgesic drugs was not significantly different among the treatment groups (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. changes in the volume of haematoma assessed radiologically at any point in the first 48 hours</HEADING>
<P>This outcome has not been assessed by either trial.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Number of participants requiring additional or alternative treatment</HEADING>
<P>In the Astermark trial additional doses were administered in cases where the protocol treatment regimen was not sufficient (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>). The timing of the additional doses varied. A small number (two) were administered within the first six hours after onset of treatment. The remainder during the balance of the 48-hour observation period (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>).</P>
<P>In the Young trial, participants with an insufficient treatment response within six hours of the first treatment administration were evaluated in the clinic or by telephone to consider the use of rescue medication (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). Rescue medication was defined as additional haemostatic treatment within nine hours after the first administration of trial product. A total of eight bleeding episodes for aPCC, two for rFVIIa 270 mcg/kg and two for rFVIIa 90 mcg/kg x 3 doses required additional medication. The difference between rFVIIa 270 mcg/kg versus aPCC was statistically significant (P = 0.032). The efficacy difference between the aPCC treatment group and the rFVIIa 90 mcg/kg x 3 doses did not reach statistical difference (P = 0.069). Full details of the results about this outcome were provided in the additional tables (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Number of participants with adverse effects (thromboses; allergic reactions)</HEADING>
<P>The Astermark trial did not report any trial-related or drug-related adverse effects (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>).</P>
<P>The Young trial did not report any thrombotic, fatal or clinical laboratory adverse events; however, it did record 32 treatment emergent adverse events in 14 participants. Of these three were in the rFVIIa 270 mcg/kg group, five were in the rFVIIa 90 mcg/kg x 3 doses group and six were in the aPCC group. None were considered to be related to the trial drug (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Correction of abnormal haemostatic laboratory test results</HEADING>
<P>This outcome has not been assessed in either trial. It has to be noted that no commonly available test exists to monitor the effect of by-passing agents (both aPCC and rFVIIa).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-10-19 12:24:50 +0100" MODIFIED_BY="Tracey Remmington">
<P>Since the previous version of this review (<LINK REF="REF-Iorio-2010" TYPE="REFERENCE">Iorio 2010</LINK>), 18 new potentially relevant references were found. Five trials were added to the excluded studies list and we did not find any further eligible trials. Therefore, results presented in this update continue to refer to the two trials already included in the 2010 version of this review (<LINK REF="REF-Iorio-2010" TYPE="REFERENCE">Iorio 2010</LINK>). However, we were successful in obtaining additional data enabling us to perform the marginal probabilities analysis, although data were still not combined in a formal meta-analysis (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>; <LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). The new data allowed us to report odds ratios (OR) and to take into account information provided by both treatment periods in the cross-over trials. There is no change in statistical non-significance of the results. Overall, both the included trials showed methodological flaws. Both the treatments were shown to be effective and safe and can be used to treat bleeding in people with haemophilia with inhibitors, but were not able to prove superiority of one treatment over the other. It is to be noted that the Astermark trial was designed and analysed as a equivalence trial (<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>); the Young trial was aimed at comparing two different dosages of recombinant factor VIIa (rFVIIa) and used activated prothrombin complex concentrates (aPCC) as a reference, without pre-stating any equivalence range (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). The high number of dropouts in both trials is an important limitation. These data do not show whether the treatments were equivalent or whether one is superior to the other. Due to the widespread use in clinical practice of both by-passing agents, their efficacy was considered as already proven, and no placebo group was felt to be needed. A significant percentage of dropouts was recorded in both trials, and the Young trial was prematurely discontinued (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). We would like to highlight that we found a relevant difference in treatment efficacy independent of the drug used, i.e. aPCC or rFVIIa, among the two trials (median efficacy of 80% at six hours in the Astermark trial and 40% in the Young trial); this means that both trials showed similar effectiveness of treatment. The difference in median efficacy rates is likely to be related to the subjective nature of the outcome measures or trial protocols or both. With regards to outcome assessment, it is important to note that no objective method is fully validated as far as joint bleeding is concerned. Similarly, there is no general consensus on when assessing the anti-haemorrhagic effect. The two trials used different scales and assessment times, and in particular the Young trial used a composite algorithm to give an overall judgement of the participants response over a wide range of assessment times (<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>). How easily the results of the trials included in the present review can be reproduced in different contexts is hard to say.</P>
<P>Based on the available randomised evidence, it is not possible to consider one treatment more efficacious or safer than the other. Other systematic reviews may help in the choice of the more effective concentrates by reviewing non-randomised evidence (<LINK REF="REF-Lloyd-Jones-2003" TYPE="REFERENCE">Lloyd Jones 2003</LINK>); or by using a Bayesian approach to pool randomised and non-randomised evidence (<LINK REF="REF-Treur-2009" TYPE="REFERENCE">Treur 2009</LINK>); or by focusing on economical aspects (<LINK REF="REF-Knight-2009" TYPE="REFERENCE">Knight 2009</LINK>). Another potentially relevant issue, not considered in this systematic review, is that of viral safety of the concentrates under evaluation. The general considerations about the safety of recombinant and plasma-derived factor VIII and IX concentrates might apply also to bypassing agents (rFVIIa and aPCC). Another aspect to be taken into account is that aPCC contains traces of factor VIII and could possibly induce an anamnestic response to be potentially avoided in patients candidate to immunotolerance treatment.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-10-19 12:24:26 +0100" MODIFIED_BY="Tracey Remmington">
<IMPLICATIONS_PRACTICE MODIFIED="2015-10-19 12:24:26 +0100" MODIFIED_BY="Tracey Remmington">
<P>Based on the separate analysis of the two available randomised trials, rFVIIa and aPCC were found to be similar in efficacy and in causing a low risk of thromboembolic complications. Both drugs can be administered as single intravenous bolus (270 mcg/kg of rFVIIa, 75 to 100 IU/kg of aPCC). Other non-randomised evidence can be usefully taken into account in the choice of the more appropriate treatment in clinical practice. The choice between different regimens of rFVIIa is beyond the scope of this review, and should be mainly based on general considerations about the use of recombinant versus plasma-derived concentrates in specific categories of people (i.e. children).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-05-01 13:19:15 +0100" MODIFIED_BY="[Empty name]">
<P>There is need for further well-designed, adequately-powered randomised controlled trials to assess the relative benefits and risks of using rFVIIa compared to human plasma-derived concentrates in people with haemophilia with inhibitors. It is advisable that researchers in the field define commonly agreed objective outcome measures in order to enable easier pooling of their results thus increasing the power of comparisons. To the same, scope reporting concordant and discordant pairs in cross-over trials would be recommended. Both tasks are difficult to pursue, but very relevant and should be sought in view of the high societal costs of treating people with haemophilia with inhibitors.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-06-04 13:19:53 +0100" MODIFIED_BY="Tracey Remmington">
<P>We would like to acknowledge the contributions of Dr Daniel Hind, Dr Myfanwy Lloyd-Jones and Miss Suzy Paisley who were members of the original review team (along with Dr Michael Makris) and developed the protocol and published the first version of this review. We also thank the authors and sponsors of the included trials for kindly providing the additional data we requested.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-10-16 13:24:42 +0100" MODIFIED_BY="Tracey Remmington">
<P>Davide Matino declares no conflict of interest.</P>
<P>Michael Makris has received fees for consultancy and sponsorship to attend scientific meetings from Baxter Healthcare and NovoNordisk.</P>
<P>Kerry Dwan declares no conflict of interest.</P>
<P>Roberto D'Amico declares no conflict of interest.</P>
<P>Alfonso Iorio has acted as paid lecturer and has been reimbursed for participation at International Congresses by both NovoNordisk and Baxter Healthcare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-01-12 16:52:32 +0000" MODIFIED_BY="[Empty name]">
<P>Contributions to the current update:</P>
<P>DM is the lead reviewer and guarantor of the review.</P>
<P>AI and DM screened the search results, screened retrieved papers against inclusion criteria and entered data into RevMan.</P>
<P>KD performed the statistical analysis</P>
<P>DM, AI, and MM drafted the update of the review</P>
<P>MM and AI provided a clinical perspective.</P>
<P>------------------------------------------------------------------------------------------</P>
<P>Contributions for Issue 8, 2010<BR/>
</P>
<P>AI is the lead reviewer and guarantor of the review.</P>
<P>AI and DM screened the search results, screened retrieved papers against inclusion criteria and entered data into RevMan.</P>
<P>AI, DM and MM drafted the update of the review</P>
<P>MM provided a clinical perspective.</P>
<P>-----------------------------------------<BR/>Review up to Issue 2, 2006<BR/>DH was the guarantor of the review.<BR/>DH coordinated the review.<BR/>DH, MLJ and MM drafted the title.<BR/>DH and MM drafted the protocol.<BR/>DH and MLJ screened the search results.<BR/>DH organised the retrieval of papers.<BR/>DH and MLJ screened retrieved papers against inclusion criteria.<BR/>DH entered data into RevMan.<BR/>DH, SP and MLJ provided a methodological perspective.<BR/>MM provided a clinical perspective.<BR/>DH and MLJ wrote the review.<BR/>SP secured funding for the review.<BR/>SP, MLJ, Chris Knight and Jeremy Wight and Elizabeth Currie performed previous work that was the foundation of current study.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-10-19 12:32:20 +0100" MODIFIED_BY="Tracey Remmington">
<P>The review protocol was modified to include people with haemophilia A and haemophilia B, since no difference exists in the treatment of individuals with inhibitor in the two conditions. Even if most of the individuals with inhibitors are people with haemophilia A (inhibitor occurrence in haemophilia B is much more rare), there is no reason to limit the review to haemophilia A.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2010-07-07 12:48:38 +0100" MODIFIED_BY="[Empty name]">
<P>The current review was originally based on a previous systematic review of the management of inhibitors in haemophilia A funded by the London NHS Directorate of Health and Social Care:</P>
<P>Wight J, Lloyd Jones M, Knight C, Paisley S, Currie E. The management of inhibitors in haemophilia A: a systematic review and economic model. London: London NHS Directorate of Health and Social Care, 2002.</P>
<P>Paisley S, Wight J, Currie E, Knight C. The management of inhibitors in haemophilia A: introduction and systematic review of current practice. Haemophilia. 2003;9:405-417</P>
<P>Wight J, Paisley, S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9:418-435.</P>
<P>Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003;9:436-463.</P>
<P>Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003;9:464-520.</P>
<P>Knight C, Paisley S, Wight J, Jones ML. Economic modelling of different treatment strategies for haemophilia A with high responding inhibitors. Haemophilia. 2003;9:521-540.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-10-29 10:58:42 +0000" MODIFIED_BY="Tracey Remmington">
<STUDIES MODIFIED="2015-10-19 12:27:50 +0100" MODIFIED_BY="Tracey Remmington">
<INCLUDED_STUDIES MODIFIED="2015-09-17 11:00:28 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY DATA_SOURCE="PUB" ID="STD-Astermark-2007" MODIFIED="2015-09-17 11:00:28 +0100" MODIFIED_BY="Tracey Remmington" NAME="Astermark 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-09-17 11:00:28 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Astermark J, Donfiled SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al</AU>
<TI>A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study</TI>
<SO>Blood</SO>
<YR>2007</YR>
<VL>109</VL>
<NO>2</NO>
<PG>546-51</PG>
<IDENTIFIERS MODIFIED="2009-07-02 14:27:44 +0100" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-02 14:28:17 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carllson KS, Astermark J, Donfield SM, Berntorp E</AU>
<TI>Health-Economic analysis of alternative bypassing agent in haemophilia complicated by an inhibitor - the FEIBA NovoSeven comparative study (FENOC)</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<PG>457</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-06-25 16:02:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-06-25 16:02:07 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1182/blood-2006-04-017988"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young-2008" MODIFIED="2009-07-02 14:30:03 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Young 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-02 14:30:03 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Young G, Shaffer FE, Rojas P, Seremetis S</AU>
<TI>Single 270 mcg/kg -dose rFVIIa versus standard 90 mcg/kg - dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison</TI>
<SO>Haemophilia</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>2</NO>
<PG>287-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-06-25 15:56:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-06-25 15:56:57 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/j.1365-2516.2007.01601.x"/>
</IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-10-19 12:27:50 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY DATA_SOURCE="PUB" ID="STD-Chuansumrit-2000" NAME="Chuansumrit 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chuansumrit A, Isarangkura P, Angchaisuksiri P, Sriudomporn N, Tanpowpong K, Hathirat P, et al</AU>
<TI>Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection</TI>
<SO>Haemophilia</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>2</NO>
<PG>61-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Paula-2012" MODIFIED="2015-10-19 12:27:23 +0100" MODIFIED_BY="Tracey Remmington" NAME="de Paula 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-10-19 12:27:23 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Paula EV, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, et al</AU>
<TI>Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2012</YR>
<VL>10</VL>
<NO>1</NO>
<PG>81-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kavakli-2006" MODIFIED="2009-07-02 14:30:45 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Kavakli 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-02 14:30:45 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kent G</AU>
<TI>Home treatment of haemarthroses using a single dose regimen of recombinant activated factor seven in patients with haemophilia and inhibitors. A multi-center, randomized, double-blind, cross-over trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2006</YR>
<VL>95</VL>
<NO>4</NO>
<PG>600-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ljung-2013" MODIFIED="2015-05-01 14:08:03 +0100" MODIFIED_BY="[Empty name]" NAME="Ljung 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-05-01 14:08:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ljung R, Karim FA, Saxena K, Suzuki T, Arkhammar P, Rosholm A, et al</AU>
<TI>40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2013</YR>
<VL>11</VL>
<NO>7</NO>
<PG>1260-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lusher-1998" NAME="Lusher 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, et al</AU>
<TI>A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group</TI>
<SO>Haemophilia</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>6</NO>
<PG>790-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Mahlangu-2012" MODIFIED="2015-05-01 14:09:00 +0100" MODIFIED_BY="[Empty name]" NAME="Mahlangu 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-05-01 14:09:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahlangu JN, Coetzee MJ, Laffan M, Windyga J, Yee TT, Schroeder J, et al</AU>
<TI>Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2012</YR>
<VL>10</VL>
<NO>5</NO>
<PG>773-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00108758" MODIFIED="2015-10-19 12:27:33 +0100" MODIFIED_BY="Tracey Remmington" NAME="NCT00108758" YEAR="2005">
<REFERENCE MODIFIED="2015-10-19 12:27:33 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00108758</AU>
<TI>Exploratory, multicenter, randomized, double-blind, uncontrolled trial evaluating the efficacy of activated rFVII (Novoseven) in secondary bleeding prophylaxis in congenital hemophilia A or B patients with inhibitors</TI>
<SO>clinicaltrials.gov/show/ NCT00108758</SO>
<YR>(accessed 23 October 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01561391" MODIFIED="2015-10-19 12:27:43 +0100" MODIFIED_BY="Tracey Remmington" NAME="NCT01561391" YEAR="1998">
<REFERENCE MODIFIED="2015-10-19 12:27:43 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01561391</AU>
<TI>Safety and efficacy of activated human recombinant FVIIa in patients with inhibitors during and after major surgery</TI>
<SO>clinicaltrials.gov/show/NCT01561391(accessed 5 December 2012)</SO>
<YR>(accessed 5 December 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pruthi-2007" MODIFIED="2009-07-02 14:32:31 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Pruthi 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-02 14:32:18 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pruthi RK, Matthew P. Valentino LA, Sumner MJ, Seremetis S, Hoots WK</AU>
<TI>Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open label, randomized multicenter trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2007</YR>
<VL>98</VL>
<NO>4</NO>
<PG>726-32</PG>
<IDENTIFIERS MODIFIED="2009-07-02 14:32:18 +0100" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-07-02 14:32:31 +0100" MODIFIED_BY="Nikki Jahnke"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santagostino-2006" MODIFIED="2009-07-02 14:31:53 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Santagostino 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-02 14:31:53 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM</AU>
<TI>A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>2</NO>
<PG>367-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seremetis-1994" NAME="Seremetis 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seremetis SV</AU>
<TI>The clinical use of factor VIIa in the treatment of factor VIII inhibitor patients</TI>
<SO>Seminars in Hematology</SO>
<YR>1994</YR>
<VL>31</VL>
<NO>2 Suppl 4</NO>
<PG>53-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shapiro-1998" MODIFIED="2015-10-19 12:27:50 +0100" MODIFIED_BY="Tracey Remmington" NAME="Shapiro 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooper HA, Gilchrist GS, Hoots WK, Shapiro A</AU>
<TI>Comparison of two doses of recombinant factor VIIa for producing hemostasis during and after surgery in patients with hemophilia A or B and inhibitors and patients with acquired inhibitors. [abstract]</TI>
<SO>Blood</SO>
<YR>1997</YR>
<VL>90</VL>
<NO>10 Suppl 1 Pt 1</NO>
<PG>600a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooper HA, Hoots WK, Shapiro A</AU>
<TI>Comparison of two doses of recombinant factor Vlla (rFVlla) for producing hemostasis during and after surgery in patients (PTS) with hemophilia A or B and inhibitors and PTS with acquired inhibitors [abstract]</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1997</YR>
<VL>Suppl</VL>
<PG>167-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-10-19 12:27:50 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA</AU>
<TI>Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>5</NO>
<PG>773-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villar-2004" NAME="Villar 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villar A, Aronis S, Morfini M, Santagostino E, Auerswald G, Thomsen HF, et al</AU>
<TI>Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A</TI>
<SO>Haemophilia</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>4</NO>
<PG>352-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-06-25 16:28:34 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2015-01-12 15:40:56 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-10-29 10:58:42 +0000" MODIFIED_BY="Tracey Remmington">
<ADDITIONAL_REFERENCES MODIFIED="2015-10-29 10:58:42 +0000" MODIFIED_BY="Tracey Remmington">
<REFERENCE ID="REF-Athale-2014" MODIFIED="2015-06-04 12:43:04 +0100" MODIFIED_BY="Tracey Remmington" NAME="Athale 2014" TYPE="COCHRANE_REVIEW">
<AU>Athale AH, Marcucci M, Iorio A</AU>
<TI>Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-06-04 12:43:04 +0100" MODIFIED_BY="Tracey Remmington">
<IDENTIFIER MODIFIED="2015-06-04 12:43:04 +0100" MODIFIED_BY="Tracey Remmington" TYPE="DOI" VALUE="10.1002/14651858.CD010561.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Becker-1993" MODIFIED="2009-07-14 14:36:35 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Becker 1993" TYPE="JOURNAL_ARTICLE">
<AU>Becker MP, Balagtas CC</AU>
<TI>Marginal modelling of binary cross-over data</TI>
<SO>Biometrics</SO>
<YR>1993</YR>
<VL>49</VL>
<NO>4</NO>
<PG>997-1009</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dimichele-2002" MODIFIED="2009-06-26 14:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="Dimichele 2002" TYPE="JOURNAL_ARTICLE">
<AU>Dimichele D</AU>
<TI>Inhibitors: resolving diagnostic and therapeutic dilemmas</TI>
<SO>Haemophilia</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>3</NO>
<PG>280-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DiMichele-2007" MODIFIED="2015-10-29 10:58:42 +0000" MODIFIED_BY="Tracey Remmington" NAME="DiMichele 2007" TYPE="JOURNAL_ARTICLE">
<AU>DiMichele D</AU>
<TI>Inhibitor development in haemophilia B: an orphan disease in need of attention</TI>
<SO>British Journal of Haematology</SO>
<YR>2007</YR>
<VL>138</VL>
<NO>3</NO>
<PG>305-15</PG>
<IDENTIFIERS MODIFIED="2009-07-09 07:29:26 +0100" MODIFIED_BY="Davide Matino">
<IDENTIFIER MODIFIED="2009-07-09 07:29:26 +0100" MODIFIED_BY="Davide Matino" TYPE="DOI" VALUE="10.1111/j.1365-2141.2007.06657.x "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2009-07-14 16:55:56 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analysis involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ewenstein-1997" MODIFIED="2010-01-07 12:43:51 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Ewenstein 1997" TYPE="JOURNAL_ARTICLE">
<AU>Ewenstein BM, Takemoto C, Warrier I, Lusher J, Saidi P, Eisele J, et al</AU>
<TI>Nephrotic syndrome as a complication of immune tolerance in hemophilia B</TI>
<SO>Blood</SO>
<YR>1997</YR>
<VL>89</VL>
<NO>3</NO>
<PG>1115-6</PG>
<IDENTIFIERS MODIFIED="2009-08-07 10:51:11 +0100" MODIFIED_BY="Davide Matino"/>
</REFERENCE>
<REFERENCE ID="REF-Goodeve-2003" MODIFIED="2009-06-26 14:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="Goodeve 2003" TYPE="JOURNAL_ARTICLE">
<AU>Goodeve AC, Peake IR</AU>
<TI>The molecular basis of hemophilia a: genotype-phenotype relationships and inhibitor development</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>1</NO>
<PG>23-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hay-2000" MODIFIED="2009-06-26 14:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="Hay 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hay CRM, Baglin TP, Collins PW, Hill FGH, Keeling DM</AU>
<TI>The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO)</TI>
<SO>British Journal of Haematology</SO>
<YR>2000</YR>
<VL>111</VL>
<NO>1</NO>
<PG>78-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hedner-2000" MODIFIED="2009-06-26 14:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="Hedner 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hedner U</AU>
<TI>Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>4</NO>
<PG>363-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-07-14 16:56:40 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knight-2009" MODIFIED="2009-07-02 14:34:38 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Knight 2009" TYPE="JOURNAL_ARTICLE">
<AU>Knight C, Dano AM, Kennedy-Martin T</AU>
<TI>A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors</TI>
<SO>Haemophilia</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>2</NO>
<PG>405-19</PG>
<IDENTIFIERS MODIFIED="2009-06-25 17:32:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-06-25 17:32:39 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/j.1365-2516.2008.01969.x"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kreuz-2002" MODIFIED="2009-06-26 14:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="Kreuz 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kreuz W, Ettingshausen CE, Zyschka A, Oldenberg J, Saguer IM, Ehrenforth S, et al</AU>
<TI>Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>3</NO>
<PG>285-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lloyd-Jones-2003" MODIFIED="2009-06-26 14:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="Lloyd Jones 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd Jones M, Wight J, Paisley S, Knight C</AU>
<TI>Control of bleeding in patients with haemophilia A with inhibitors: a systematic review</TI>
<SO>Haemophilia</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>4</NO>
<PG>464-520</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mannucci-2001" MODIFIED="2009-06-26 14:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="Mannucci 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mannucci PM, Tuddenham EG</AU>
<TI>The hemophilias - from royal genes to gene therapy</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>23</NO>
<PG>1773-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rizza-2001" MODIFIED="2009-06-26 14:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="Rizza 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rizza CR, Spooner RJ, Giangrande PL; UK Haemophilia Centre Doctors' Organization (UKCDO)</AU>
<TI>Treatment of haemophilia in the United Kingdom 1981-1996</TI>
<SO>Haemophilia</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>4</NO>
<PG>349-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-1977" MODIFIED="2015-10-19 12:28:01 +0100" MODIFIED_BY="Tracey Remmington" NAME="Thomas 1977" TYPE="JOURNAL_ARTICLE">
<AU>Thomas T, Williams H, Williams Y, Hunt J</AU>
<TI>FEIBA in haemophiliacs with factor VIII inhibitor</TI>
<SO>BMJ</SO>
<YR>1977</YR>
<VL>1</VL>
<NO>6052</NO>
<PG>52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Treur-2009" MODIFIED="2009-07-02 14:34:27 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Treur 2009" TYPE="JOURNAL_ARTICLE">
<AU>Treur MJ, McCracken F, Heeg B, Joshi AV, Botteman MF, De Charro F, et al</AU>
<TI>Efficacy of recombinant activated factor seven vs activated prothrombin complex concentrates for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression</TI>
<SO>Haemophilia</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>2</NO>
<PG>420-36</PG>
<IDENTIFIERS MODIFIED="2009-06-25 17:30:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-06-25 17:30:34 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/j.1365-2516.2008.01956.x"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-UKHCDO-2003" MODIFIED="2009-06-26 14:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="UKHCDO 2003" TYPE="JOURNAL_ARTICLE">
<AU>United Kingdom Haemophilia Doctors' Organisation</AU>
<TI>Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders</TI>
<SO>Haemophilia</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>1</NO>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2001" MODIFIED="2009-06-26 14:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="White 2001" TYPE="JOURNAL_ARTICLE">
<AU>White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al</AU>
<TI>Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2001</YR>
<VL>85</VL>
<NO>3</NO>
<PG>560</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yee-1999" MODIFIED="2009-06-26 14:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="Yee 1999" TYPE="JOURNAL_ARTICLE">
<AU>Yee TT, Pasi KJ, Lilley PA, Lee CA</AU>
<TI>Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97</TI>
<SO>British Journal of Haematology</SO>
<YR>1999</YR>
<VL>104</VL>
<NO>4</NO>
<PG>909-14</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-07-18 15:41:27 +0100" MODIFIED_BY="Tracey Remmington">
<REFERENCE ID="REF-Iorio-2010" MODIFIED="2012-07-18 15:41:27 +0100" MODIFIED_BY="Tracey Remmington" NAME="Iorio 2010" TYPE="COCHRANE_REVIEW">
<AU>Iorio A, Matino D, D'Amico R, Makris M</AU>
<TI>Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2012-07-18 15:41:27 +0100" MODIFIED_BY="Tracey Remmington">
<IDENTIFIER MODIFIED="2012-07-18 15:41:27 +0100" MODIFIED_BY="Tracey Remmington" TYPE="DOI" VALUE="10.1002/14651858.CD004449.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Antunes-2013" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Antunes 2013" TYPE="JOURNAL_ARTICLE">
<AU>Antunes SV, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman-Becerra N, et al</AU>
<TI>Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors</TI>
<SO>Haemophilia</SO>
<YR>2013</YR>
<VL>20</VL>
<NO>1</NO>
<PG>65-72</PG>
<PB>Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom)</PB>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="961365"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000036"/>
<IDENTIFIER TYPE="EMBASE" VALUE="2013812414"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Antunes-2013a" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Antunes 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Antunes S, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman-Becerra N, et al</AU>
<TI>A prospective, open-label, randomized, parallel study with AICC to evaluate the efficacy and safety of prophylactic vs. on-demand treatment in hemophilia A or B subjects with inhibitors [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis : JTH</SO>
<YR>2013</YR>
<VL>11 Suppl 2</VL>
<PG>982, Abstract no: PB 4.58-6</PG>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1014799"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000230"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Paula-2011" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="de Paula 2011" TYPE="JOURNAL_ARTICLE">
<AU>de Paula E, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, et al</AU>
<TI>Clinical and laboratory results from adept&#8482; 1, a phase 2 trial investigating the use of recombinant activated FVII analogue in congenital haemophilia patients with inhibitors [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis : JTH</SO>
<YR>2011</YR>
<VL>9 Suppl 2</VL>
<PG>512, Abstract no: O-WE-029</PG>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1015344"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000265"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eshghi-2013" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Eshghi 2013" TYPE="JOURNAL_ARTICLE">
<AU>Eshghi P, Kamyar K, Abolghasemi H, Karimi M, Faranoush M, Toogeh G, et al</AU>
<TI>Comparison of efficacy and safety between aryogen recombinant activated factor VII (Aryoseven) and Novoseven® in the main on-label (approved) indications of recombinant activated factor VII in Iran [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis : JTH</SO>
<YR>2013</YR>
<VL>11 Suppl 2</VL>
<PG>30, Abstract no: EHF03</PG>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1037793"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000223"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Faranoush-2013" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Faranoush 2013" TYPE="JOURNAL_ARTICLE">
<AU>Faranoush M, Hassan A, Karimi M, Toogeh G, Eshghi P, Managchi MR, et al</AU>
<TI>Comparison of recombinant coagulation factor VII (ARYOSEVEN®) with NOVOSEVEN® in patients with FVIII and IX deficiency with an inhibitor [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis : JTH</SO>
<YR>2013</YR>
<VL>11 Suppl 2</VL>
<PG>568, Abstract no: PB 1.50-6</PG>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1013534"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000221"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Faranoush-2013a" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Faranoush 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Faranoush M, Hassan A, Toogeh G, Karimi M, Eshghi P, Managchi MR, et al</AU>
<TI>The comparison of efficacy between recombinant activated factor VII (ARYOSEVEN®) and NOVOSEVEN® in patients with congenital factor VII deficiency [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis : JTH</SO>
<YR>2013</YR>
<VL>11 Suppl 2</VL>
<PG>1198, Abstract no: PO 481</PG>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1013535"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000222"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Faranoush-2013b" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Faranoush 2013b" TYPE="JOURNAL_ARTICLE">
<AU>Faranoush M, on behalfofBVIISG</AU>
<TI>Safety and efficacy profile of a biosimilar recombinant factor VIIA in patients with factor VII deficiency [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis : JTH</SO>
<YR>2013</YR>
<VL>11 Suppl 2</VL>
<PG>32, Abstract no: EHF10</PG>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1013533"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000218"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Faranoush-2014" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Faranoush 2014" TYPE="JOURNAL_ARTICLE">
<AU>Faranoush M, Abolghasemi H, Mahboudi F, Toogeh G, Karimi M, Eshghi P, et al</AU>
<TI>A comparison of efficacy between recombinant activated factor VII (Aryoseven) and Novoseven in patients with hereditary FVIII deficiency with inhibitor</TI>
<SO>Clinical and Applied Thrombosis/hemostasis</SO>
<YR>2014</YR>
<VL>epub ahead of print</VL>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1037794"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000309"/>
<IDENTIFIER OTHERTYPE="JID:" TYPE="OTHER" VALUE="9508125"/>
<IDENTIFIER TYPE="PUBMED" VALUE="25343955"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Galstyan-2011" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Galstyan 2011" TYPE="JOURNAL_ARTICLE">
<AU>Galstyan GM, Zorenko VY, Polyanskaya TY, Sampiev M, Severova T, Konyashina N, et al</AU>
<TI>Comparison of the efficacy of two recombinant factor VIIA agents [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis : JTH</SO>
<YR>2011</YR>
<VL>9 Suppl 2</VL>
<PG>470, Abstract no: P-TU-514</PG>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1015277"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000258"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kenet-2010" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Kenet 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kenet G, Stenmo CB, Blemings A, Wegert W, Goudemand J, Krause M, et al</AU>
<TI>Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2010</YR>
<VL>103</VL>
<NO>2</NO>
<PG>351-9</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="743615"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000306"/>
<IDENTIFIER OTHERTYPE="JID:" TYPE="OTHER" VALUE="7608063"/>
<IDENTIFIER TYPE="PUBMED" VALUE="20024491"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lentz-2013" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Lentz 2013" TYPE="JOURNAL_ARTICLE">
<AU>Lentz SR, Mahlangu J, Abdul Karim FA, Andreeva T, Economou M, Ehrenforth S, et al</AU>
<TI>Multicentre, randomised, double-blinded, active-controlled, cross-over phase 3 trial on safety and efficacy of rFVIIa analogue (vareptacog alfa) in haemophilia patients with inhibitors (adept&#8482; 2) [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis : JTH</SO>
<YR>2013</YR>
<VL>11 Suppl 2</VL>
<PG>255, Abstract no: OC 83.2</PG>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1013531"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000216"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mahlangu-2013" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Mahlangu 2013" TYPE="JOURNAL_ARTICLE">
<AU>Mahlangu J, Abdul Karim F, Gorska-Kosicka M, Kaicker S, Matushita T, Recht M, et al</AU>
<TI>Anti-drug antibody formation induced by recombinant activated FVII analogue (vareptacog alfa) - results from the phase 3 adept&#8482; 2 trial haemophilia patients with inhibitors [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis : JTH</SO>
<YR>2013</YR>
<VL>11 Suppl 2</VL>
<PG>268, Abstract no: OC 83.5</PG>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1013530"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000215"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Powell-2013" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Powell 2013" TYPE="JOURNAL_ARTICLE">
<AU>Powell J, Kluft C, Moerland M, Frieling J, Valentino LA</AU>
<TI>Pharmacodynamic effects of escalating dosages of a new recombinant human Factor VIIa (LR769) in congenital hemophilia A or B patients [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis : JTH</SO>
<YR>2013</YR>
<VL>11 Suppl 2</VL>
<PG>1129, Abstract no: PO 291</PG>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1013528"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000212"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stasyshyn-2014" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Stasyshyn 2014" TYPE="JOURNAL_ARTICLE">
<AU>Stasyshyn O, Antunes S, Mamonov V, Ye X, Epstein J, Xiong Y, et al</AU>
<TI>Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study</TI>
<SO>Haemophilia</SO>
<YR>2014</YR>
<VL>20</VL>
<NO>5</NO>
<PG>644-50</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1001041"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000129"/>
<IDENTIFIER OTHERTYPE="JID:" TYPE="OTHER" VALUE="9442916"/>
<IDENTIFIER TYPE="PUBMED" VALUE="24589084"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Valentino-2013" MODIFIED="2015-05-05 13:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Valentino 2013" TYPE="JOURNAL_ARTICLE">
<AU>Valentino LA, Reijers J, Freijer J, Frieling J, Powell J</AU>
<TI>Safety and pharmacokinetics of three doses of a new recombinant human Factor VIIa (LR769) in congenital hemophilia A or B patients [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis : JTH</SO>
<YR>2013</YR>
<VL>11 Suppl 2</VL>
<PG>1130, Abstract no: PO295</PG>
<IDENTIFIERS MODIFIED="2015-05-05 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="1014801"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000233"/>
</IDENTIFIERS>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-10-19 12:32:38 +0100" MODIFIED_BY="Tracey Remmington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-10-19 12:32:38 +0100" MODIFIED_BY="Tracey Remmington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-09-17 11:26:08 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Astermark-2007">
<CHAR_METHODS MODIFIED="2015-05-01 13:49:50 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label cross-over multicentre RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-17 11:26:08 +0100" MODIFIED_BY="Tracey Remmington">
<P>Individuals with severe haemophilia A with inhibitors not undergoing ITI. A total of 66 individuals were enrolled, but 14 withdrew prior to treatment or were treated only once. Diaries for a further 4 participants were not adequately completed.</P>
<P>Age: mean 27.5 years (range 8 - 55 years).</P>
<P>Mean inhibitor titre 8.6 BU/ml (range 0 - 1800).</P>
<P>96 episodes in 48 participants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-01 13:53:06 +0100" MODIFIED_BY="[Empty name]">
<P>aPCC (FEIBA<SUP>®</SUP>) 75 - 100 IU/kg (target 85 IU/kg) as a single IV bolus.</P>
<P>Activated rFVII (NovoSeven<SUP>®</SUP>) 90 - 120 mcg/kg (target 105 mcg/kg) as IV bolus repeated after 2 hours.</P>
<P>Both treatments were administered a mean of 2 hours after bleeding onset.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-01 13:53:30 +0100" MODIFIED_BY="[Empty name]">
<P>Subjective evaluation of treatment efficacy based on a four level scale (effective, partially effective, poorly effective, not effective); efficacy was defined as effective or partially effective by participant rating at 6 hours (primary) and at various times from 2 - 48 hours (secondary).</P>
<P>Subjective evaluation of stop of bleeding (binary outcome).</P>
<P>Additonal treatments and the occurrence of re-bleeding were recorded.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-04 13:21:48 +0100" MODIFIED_BY="Tracey Remmington">
<P>Use of analgesics was allowed and its distribution in the treatment group was evaluated.</P>
<P>A significantly different number of knee (higher in Novoseven<SUP>®</SUP>-treated participants) and elbow (higher in aPCC-treated participants) bleeding events were recorded. The analysis technique used to balance for the uneven distribution of knee bleeds is unclear and not sufficiently detailed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-17 11:39:26 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Young-2008">
<CHAR_METHODS MODIFIED="2015-05-01 13:54:07 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label cross-over multicentre 3-tier RCT.</P>
<P>The comparison between rFVIIa and aPCC was open label, while the comparison between the two different rFVIIa regimens was concealed.</P>
<P>Outcome assessor was blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-17 11:39:26 +0100" MODIFIED_BY="Tracey Remmington">
<P>Individuals with severe haemophilia A and B with inhibitor (the number of participants with A and B was not separately specified). A total of 42 were randomised, with 21 completing all 3 arms of treatment.</P>
<P>Age: mean 19.5 years (range 1 - 54 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-01 13:54:57 +0100" MODIFIED_BY="[Empty name]">
<P>Activated rrF VII (NovoSeven<SUP>®</SUP>) 90 mcg/kg as IV bolus administered at 0, 3 and 6 hours.</P>
<P>Activated recombinant factor VII (NovoSeven<SUP>®</SUP>) 270 mcg/kg as single IV bolus (followed by 2 placebo infusions).</P>
<P>aPCC (FEIBA<SUP>®</SUP>) 75 IU/kg as a single IV bolus.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-01 13:55:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes</B>
</P>
<P>Number of participants requiring additional treatment.</P>
<P>
<B>Secondary outcomes</B>
</P>
<P>Subjective pain and mobility scale rating evaluated as global treatment response (composite end-point) and separately.</P>
<P>Rate of adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-01 13:55:14 +0100" MODIFIED_BY="[Empty name]">
<P>The trial states that the analysis was performed on an intention-to-treat basis, but the data seems to have been analysed on-treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>aPCC: activated prothrombin complex concentrates<BR/>BU: Bethesda units<BR/>ITI: immune tolerance induction<BR/>IV: intravenous<BR/>RCT: randomised controlled trial<BR/>rFVIIa: recombinant factor VIIa<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-05-13 10:22:49 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Chuansumrit-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised or quasi-randomised controlled trial.<BR/>Prospective, open-label, uncontrolled, observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-01 13:57:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Paula-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-01 13:57:50 +0100" MODIFIED_BY="[Empty name]">
<P>Dosage-finding trial: comparator is not an alternative therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-02 14:25:12 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Kavakli-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-02 14:25:12 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Double-blind cross-over RCT comparing two different regimens of rFVIIa.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-01 13:58:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ljung-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-01 13:58:59 +0100" MODIFIED_BY="[Empty name]">
<P>RCT comparing two different regimens of rFVIIa.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lusher-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dosage-finding trial: comparator is not an alternative therapy.<BR/>Double-blind RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-01 13:59:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahlangu-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-01 13:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>Dosage-finding trial: comparator is not an alternative therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-01 14:00:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00108758">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-01 14:00:01 +0100" MODIFIED_BY="[Empty name]">
<P>RCT comparing two different regimens of rFVIIa.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-01 14:00:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01561391">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-01 14:00:32 +0100" MODIFIED_BY="[Empty name]">
<P>RCT comparing two different regimens of rFVIIa.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-13 10:22:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pruthi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-13 10:22:49 +0100" MODIFIED_BY="[Empty name]">
<P>Open label randomised RCT comparing two different regimens of rFVIIa (90 mcg/kg boluses versus continuous infusion) in people with haemophilia undergoing major surgery.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-02 14:25:55 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Santagostino-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-02 14:25:55 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Open label cross-over RCT comparing two different regimens of rFVIIa.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Seremetis-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised or quasi-randomised controlled trial.<BR/>Phase II safety and efficacy trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shapiro-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dosage-finding trial: comparator is not an alternative therapy.<BR/>Double-blind RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Villar-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dosage-finding trial: comparator is not an alternative therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial<BR/>rFVIIa: recombinant factor VIIa</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-06-25 16:28:34 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-01-12 15:40:56 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-10-19 12:32:38 +0100" MODIFIED_BY="Tracey Remmington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-09-17 11:39:17 +0100" MODIFIED_BY="Tracey Remmington" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-17 11:39:17 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Astermark-2007">
<DESCRIPTION>
<P>Randomisation in association with the first bleeding event was performed in a block of participants equally divided into two.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 12:54:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-2008">
<DESCRIPTION>
<P>6 treatment sequences were generated by the permutation of the 3 dosing regimens. The sequences were randomly assigned to the participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-09-17 11:39:22 +0100" MODIFIED_BY="Tracey Remmington" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-17 11:39:22 +0100" MODIFIED_BY="Tracey Remmington" RESULT="NO" STUDY_ID="STD-Astermark-2007">
<DESCRIPTION>
<P>Open-label trial. A randomisation list specifying the order of treatment for enrolled participants was provided to each participating centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 12:54:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-2008">
<DESCRIPTION>
<P>The comparison between rFVIIa and aPCC was open label, while the comparison between the 2 different rFVIIa regimens was described as blinded without details about randomisation code concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-10-19 12:32:38 +0100" MODIFIED_BY="Tracey Remmington" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-10-19 12:32:38 +0100" MODIFIED_BY="Tracey Remmington" RESULT="NO" STUDY_ID="STD-Astermark-2007">
<DESCRIPTION>
<P>Blinding was not possible for physicians and participants because of difference between the 2 products (physical appearance and required volume for injection). Outcome assessment was not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-05-01 13:55:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Young-2008">
<DESCRIPTION>
<P>Participants and clinicians could not be blinded to comparison between both NovoSeven<SUP>®</SUP> treatments and the FEIBA<SUP>®</SUP> treatment due to differences in physical appearance and required volume for injection, but comparison of 2 NovoSeven<SUP>®</SUP> treatments was blinded (3 active versus 1 active and 2 placebo doses). Outcome assessment was blinded for the treatments.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-10-19 12:15:26 +0100" MODIFIED_BY="Tracey Remmington" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 12:52:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Astermark-2007">
<DESCRIPTION>
<P>The trial was analysed on a per protocol basis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-19 12:15:26 +0100" MODIFIED_BY="Tracey Remmington" RESULT="NO" STUDY_ID="STD-Young-2008">
<DESCRIPTION>
<P>The trial states that the analysis was performed on an intention-to-treat basis, but the data seems to have been analysed on-treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-07-07 12:56:41 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 12:52:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Astermark-2007">
<DESCRIPTION>
<P>Outcome data reported in the methods and the results sections correspond.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 12:56:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Young-2008">
<DESCRIPTION>
<P>Outcome data reported in the methods and results sections correspond.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-06-04 13:20:09 +0100" MODIFIED_BY="Tracey Remmington" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-04 13:20:05 +0100" MODIFIED_BY="Tracey Remmington" RESULT="NO" STUDY_ID="STD-Astermark-2007">
<DESCRIPTION>
<P>Use of analgesics allowed during the trial.</P>
<P>A significantly different number of knee (higher in participants treated with Novoseven<SUP>®</SUP>) and elbow (higher in participants treated with aPCC) bleeding events were recorded. The analysis technique used to balance for the uneven distribution of knee bleeds is unclear and not sufficiently detailed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-04 13:20:09 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Young-2008">
<DESCRIPTION>
<P>Use of analgesics allowed during the trial. Distribution of analgesics use among group was evaluated.</P>
<P>The trial was interrupted by the sponsor for unspecified reasons.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-06-26 15:40:13 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2015-10-19 12:26:52 +0100" MODIFIED_BY="Tracey Remmington">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-06-04 13:32:49 +0100" MODIFIED_BY="Tracey Remmington" NO="1">
<TITLE MODIFIED="2015-06-04 13:32:49 +0100" MODIFIED_BY="Tracey Remmington">aPCC 75-100 IU/kg vs rFVIIa 90 - 120 mcg/kg x 2 doses - Treatment efficacy judgement</TITLE>
<TABLE COLS="6" ROWS="7">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Hours (pts number)</P>
</TH>
<TH>
<P>aPCC n (%)</P>
</TH>
<TH>
<P>rFVIIa n (%)</P>
</TH>
<TH>
<P>90% CI of the difference (%)</P>
</TH>
<TH>
<P>P value</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="6">
<P>
<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>
</P>
</TD>
<TD>
<P>2 (48)</P>
</TD>
<TD>
<P>36 (75.0)</P>
</TD>
<TD>
<P>29 (60.4)</P>
</TD>
<TD>
<P>-0.73 to 29.9</P>
</TD>
<TD>
<P>0.482</P>
</TD>
</TR>
<TR>
<TD>
<P>6 (47)</P>
</TD>
<TD>
<P>38 (80.9)</P>
</TD>
<TD>
<P>37 (78.7)</P>
</TD>
<TD>
<P>-11.42 to 15.67</P>
</TD>
<TD>
<P>0.059</P>
</TD>
</TR>
<TR>
<TD>
<P>12 (45)</P>
</TD>
<TD>
<P>38 (80.0)</P>
</TD>
<TD>
<P>38 (84.4)</P>
</TD>
<TD>
<P>-18.08 to 9.19</P>
</TD>
<TD>
<P>0.101</P>
</TD>
</TR>
<TR>
<TD>
<P>24 (42)</P>
</TD>
<TD>
<P>40 (95.2)</P>
</TD>
<TD>
<P>36 (85.7)</P>
</TD>
<TD>
<P>-1.29 to 20.33</P>
</TD>
<TD>
<P>0.202</P>
</TD>
</TR>
<TR>
<TD>
<P>36 (41)</P>
</TD>
<TD>
<P>41 (100)</P>
</TD>
<TD>
<P>37 (90.2)</P>
</TD>
<TD>
<P>2.13 to 17.38</P>
</TD>
<TD>
<P>0.129</P>
</TD>
</TR>
<TR>
<TD>
<P>48 (41)</P>
</TD>
<TD>
<P>40 (97.6)</P>
</TD>
<TD>
<P>35 (85.4)</P>
</TD>
<TD>
<P>2.05 to 22.34</P>
</TD>
<TD>
<P>0.325</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>The table reports the number and % of participants who judged the treatment efficacious for any treatment and any time point. The 90% CIs of the difference test the hypothesis of equivalence between the treatments. When considering the difference at 2 hours, it has to be taken into account that this time point is before the administration of the second rFVIIa bolus.</P>
<P>aPCC: activated prothrombin complex concentrates<BR/>CI: confidence interval<BR/>rFVIIa: recombinant factor VIIa<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2015-10-19 12:26:52 +0100" MODIFIED_BY="Tracey Remmington" NO="2">
<TITLE MODIFIED="2015-06-04 13:31:32 +0100" MODIFIED_BY="Tracey Remmington">aPCC 75 - 100 IU/kg vs rFVIIa 90 - 120 mcg/kg x 2 doses - Bleeding stop</TITLE>
<TABLE COLS="6" ROWS="7">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Hours (number of participants)</P>
</TH>
<TH>
<P>aPCC (%)</P>
</TH>
<TH>
<P>rFVIIa (%)</P>
</TH>
<TH>
<P>90% CI of the difference (%)</P>
</TH>
<TH>
<P>P value</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="6">
<P>
<LINK REF="STD-Astermark-2007" TYPE="STUDY">Astermark 2007</LINK>
</P>
</TD>
<TD>
<P>2 (47)</P>
</TD>
<TD>
<P>53.2</P>
</TD>
<TD>
<P>38.3</P>
</TD>
<TD>
<P>0.06 to 29.72</P>
</TD>
<TD>
<P>0.495</P>
</TD>
</TR>
<TR>
<TD>
<P>6 (46)</P>
</TD>
<TD>
<P>76.1</P>
</TD>
<TD>
<P>65.2</P>
</TD>
<TD>
<P>-2.73 to 24.47</P>
</TD>
<TD>
<P>0.309</P>
</TD>
</TR>
<TR>
<TD>
<P>12 (45)</P>
</TD>
<TD>
<P>77.8</P>
</TD>
<TD>
<P>75.6</P>
</TD>
<TD>
<P>-11.92 to 16.37</P>
</TD>
<TD>
<P>0.069</P>
</TD>
</TR>
<TR>
<TD>
<P>24 (42)</P>
</TD>
<TD>
<P>90.5</P>
</TD>
<TD>
<P>85.7</P>
</TD>
<TD>
<P>-4.75 to 14.28</P>
</TD>
<TD>
<P>0.038</P>
</TD>
</TR>
<TR>
<TD>
<P>36 (41)</P>
</TD>
<TD>
<P>95.1</P>
</TD>
<TD>
<P>87.8</P>
</TD>
<TD>
<P>-1.45 to 16.09</P>
</TD>
<TD>
<P>0.075</P>
</TD>
</TR>
<TR>
<TD>
<P>48 (41)</P>
</TD>
<TD>
<P>95.1</P>
</TD>
<TD>
<P>92.7</P>
</TD>
<TD>
<P>4.48 to 9.36</P>
</TD>
<TD>
<P>0.001</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>The table reports the number and % of participants who judged the treatment efficacious for any treatment and any time point. The 90% CIs of the difference test the hypothesis of equivalence between the treatments. When considering the difference at 2 hours, it has to be taken into account that this time point is before the administration of the second rFVIIa bolus.</P>
<P>aPCC: activated prothrombin complex concentrates<BR/>CI: confidence interval<BR/>rFVIIa: recombinant factor VIIa</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2015-06-04 13:30:45 +0100" MODIFIED_BY="Tracey Remmington" NO="3">
<TITLE MODIFIED="2015-06-04 13:30:45 +0100" MODIFIED_BY="Tracey Remmington">aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses - Pain scale</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>rFVIIa 270 mcg/kg</P>
<P>(N = 24)</P>
</TH>
<TH>
<P>rFVIIa 90 mcg/kg x 3</P>
<P>(n = 22)</P>
</TH>
<TH>
<P>aPCC 75 IU/kg</P>
<P>(n = 22)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>
</P>
</TD>
<TD>
<P>Positive treatment response (%)</P>
</TD>
<TD>
<P>45.8</P>
</TD>
<TD>
<P>54.5</P>
</TD>
<TD>
<P>27.3</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>The response was globally evaluated 9 hours after treatment. The positive response were defined as at least 3 positive assessments at 1, 3, 6 and 9 hours. The positive assessment was defined on the base of a 3-level scale (more pain, no difference, less pain). There were no statistically significant differences between treatments (P = 0.219).</P>
<P>aPCC: activated prothrombin complex concentrates<BR/>rFVIIa: recombinant factor VIIa</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2015-06-04 13:32:17 +0100" MODIFIED_BY="Tracey Remmington" NO="4">
<TITLE MODIFIED="2015-06-04 13:32:17 +0100" MODIFIED_BY="Tracey Remmington">aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses - Mobility scale</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>rFVIIa 270 mcg/kg</P>
<P>(N = 24)</P>
</TH>
<TH>
<P>rFVIIa 90 mcg/kg x 3</P>
<P>(n = 22)</P>
</TH>
<TH>
<P>aPCC 75 IU/kg</P>
<P>(n = 22)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>
</P>
</TD>
<TD>
<P>Positive treatment response (%)</P>
</TD>
<TD>
<P>25.0</P>
</TD>
<TD>
<P>45.5</P>
</TD>
<TD>
<P>22.7</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>The response was globally evaluated 9 hours after treatment. The positive response were defined as at least 3 positive assessments at 1, 3, 6 and 9 hours. The positive assessment was defined on the base of a 3-level scale (more mobility, no difference, less mobility). There were no statistically significant differences between treatments (P = 0.903).</P>
<P>aPCC: activated prothrombin complex concentrates<BR/>rFVIIa: recombinant factor VIIa</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2015-09-17 10:54:46 +0100" MODIFIED_BY="Tracey Remmington" NO="5">
<TITLE MODIFIED="2015-06-04 13:32:42 +0100" MODIFIED_BY="Tracey Remmington">aPCC 75 IU/kg vs rFVIIa 270 mcg/kg vs rFVIIa 90 mcg/kg x 3 doses - Rescue medication use</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>rFVIIa 270 mcg/kg</P>
<P>(n = 24)</P>
</TH>
<TH>
<P>rFVIIa 90 mcg/kg x 3</P>
<P>(n = 22)</P>
</TH>
<TH>
<P>aPCC 75 IU/kg</P>
<P>(n = 22)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Young-2008" TYPE="STUDY">Young 2008</LINK>
</P>
</TD>
<TD>
<P>Participants requiring rescue medication n (%)</P>
</TD>
<TD>
<P>2 (8.3)</P>
</TD>
<TD>
<P>2 (9.1)</P>
</TD>
<TD>
<P>8 (36.4)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Participants with an insufficient treatment response within 6 hours of the first treatment administration were evaluated in the clinic or by phone to consider the use of rescue medication. Rescue medication was defined as additional haemostatic treatment within 9 hours post first administration of trial product. The difference between rFVIIa 270 mcg/kg vs aPCC was statistically significant (P = 0.032). The efficacy difference between the aPCC treatment group and the rFVIIa 90 x 3 mcg/kg did not reach statistical difference (P = 0.069).</P>
<P>aPCC: activated prothrombin complex concentrates<BR/>rFVIIa: recombinant factor VIIa</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-06-04 13:29:45 +0100" MODIFIED_BY="Tracey Remmington">
<COMPARISON ID="CMP-001" MODIFIED="2015-06-04 13:29:45 +0100" MODIFIED_BY="Tracey Remmington" NO="1">
<NAME>aPCC 75 - 100 IU/kg vs rFVIIa 90 - 120 mcg/kg x 2 doses</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:30:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="264" TOTAL_2="264" WEIGHT="0.0" Z="0.0">
<NAME>Treatment efficacy judgement</NAME>
<GROUP_LABEL_1>rFVIIa</GROUP_LABEL_1>
<GROUP_LABEL_2>APCC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rFVIIa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APCC</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:27:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>At 2 hours</NAME>
<IV_DATA CI_END="4.643294747809136" CI_START="0.8307518131423896" EFFECT_SIZE="1.9640329759698472" ESTIMABLE="YES" ESTIMATE="0.675" LOG_CI_END="0.6668262527560167" LOG_CI_START="-0.08052870218662676" LOG_EFFECT_SIZE="0.29314877528469496" MODIFIED="2014-09-12 10:14:49 +0100" MODIFIED_BY="[Empty name]" ORDER="3" SE="0.439" STUDY_ID="STD-Astermark-2007" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:28:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>At 6 hours</NAME>
<IV_DATA CI_END="3.1066395023113564" CI_START="0.4191436422964762" EFFECT_SIZE="1.141108319267235" ESTIMABLE="YES" ESTIMATE="0.132" LOG_CI_END="0.4922908601940207" LOG_CI_START="-0.3776371169715622" LOG_EFFECT_SIZE="0.05732687161122925" MODIFIED="2015-02-18 10:28:46 +0000" MODIFIED_BY="[Empty name]" ORDER="4" SE="0.511" STUDY_ID="STD-Astermark-2007" TOTAL_1="47" TOTAL_2="47" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:29:32 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>At 12 hours</NAME>
<IV_DATA CI_END="2.2572323415276503" CI_START="0.24071552541497376" EFFECT_SIZE="0.7371233743916277" ESTIMABLE="YES" ESTIMATE="-0.305" LOG_CI_END="0.3535762641951909" LOG_CI_START="-0.6184958981561745" LOG_EFFECT_SIZE="-0.13245981698049183" MODIFIED="2015-02-18 10:29:32 +0000" MODIFIED_BY="[Empty name]" ORDER="5" SE="0.571" STUDY_ID="STD-Astermark-2007" TOTAL_1="45" TOTAL_2="45" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:30:35 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>At 24 hours</NAME>
<IV_DATA CI_END="13.401541625433488" CI_START="0.49789316802257766" EFFECT_SIZE="2.583125242080516" ESTIMABLE="YES" ESTIMATE="0.949" LOG_CI_END="1.127154759626665" LOG_CI_START="-0.30286383297429303" LOG_EFFECT_SIZE="0.41214546332618596" MODIFIED="2015-02-18 10:30:35 +0000" MODIFIED_BY="[Empty name]" ORDER="6" SE="0.84" STUDY_ID="STD-Astermark-2007" TOTAL_1="42" TOTAL_2="42" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:30:40 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>At 36 hours</NAME>
<IV_DATA CI_END="79.40418057733211" CI_START="0.38421575623952287" EFFECT_SIZE="5.523435279705856" ESTIMABLE="YES" ESTIMATE="1.709" LOG_CI_END="1.8998433683448614" LOG_CI_START="-0.4154248291995469" LOG_EFFECT_SIZE="0.7422092695726574" MODIFIED="2015-02-18 10:30:40 +0000" MODIFIED_BY="[Empty name]" ORDER="7" SE="1.36" STUDY_ID="STD-Astermark-2007" TOTAL_1="41" TOTAL_2="41" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:30:43 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>At 48 hours</NAME>
<IV_DATA CI_END="26.607818495976108" CI_START="0.5961844970453452" EFFECT_SIZE="3.982859385855512" ESTIMABLE="YES" ESTIMATE="1.382" LOG_CI_END="1.4250092693654894" LOG_CI_START="-0.22461932138490134" LOG_EFFECT_SIZE="0.600194973990294" MODIFIED="2015-02-18 10:30:43 +0000" MODIFIED_BY="[Empty name]" ORDER="8" SE="0.969" STUDY_ID="STD-Astermark-2007" TOTAL_1="41" TOTAL_2="41" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-06-04 13:29:13 +0100" MODIFIED_BY="Tracey Remmington" NO="2">
<NAME>rFVIIa 270 ug/kg vs rFVIIa 90 ug/kg x 3 doses</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-05-01 13:10:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="72" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>Mobility evaluation</NAME>
<GROUP_LABEL_1>rFVIIa 270 ug/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>rFVIIa 3x90 ug/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rFVIIa 270 ug/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rFVIIa 3x90 ug/kg</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:46:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>At 1 hour</NAME>
<IV_DATA CI_END="15.369209816599204" CI_START="0.385827019694059" EFFECT_SIZE="2.4351296512898744" ESTIMABLE="YES" ESTIMATE="0.89" LOG_CI_END="1.1866515395158588" LOG_CI_START="-0.41360736172807044" LOG_EFFECT_SIZE="0.3865220888938941" MODIFIED="2014-09-12 12:56:54 +0100" MODIFIED_BY="[Empty name]" ORDER="9" SE="0.94" STUDY_ID="STD-Young-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:46:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>At 3 hours</NAME>
<IV_DATA CI_END="4.831599974227507" CI_START="0.42520763755330493" EFFECT_SIZE="1.4333294145603404" ESTIMABLE="YES" ESTIMATE="0.36" LOG_CI_END="0.6840909702783813" LOG_CI_START="-0.37139894330804" LOG_EFFECT_SIZE="0.1563460134851707" MODIFIED="2015-02-18 10:46:46 +0000" MODIFIED_BY="[Empty name]" ORDER="8" SE="0.62" STUDY_ID="STD-Young-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:47:27 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>At 6 hours</NAME>
<IV_DATA CI_END="7.087839376036654" CI_START="0.8535249098429429" EFFECT_SIZE="2.45960311115695" ESTIMABLE="YES" ESTIMATE="0.9" LOG_CI_END="0.8505138670489488" LOG_CI_START="-0.06878379962309557" LOG_EFFECT_SIZE="0.3908650337129267" MODIFIED="2015-02-18 10:47:27 +0000" MODIFIED_BY="[Empty name]" ORDER="9" SE="0.54" STUDY_ID="STD-Young-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:47:55 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>At 9 hours</NAME>
<IV_DATA CI_END="4.762547492488812" CI_START="0.7255808934635612" EFFECT_SIZE="1.858928041846342" ESTIMABLE="YES" ESTIMATE="0.62" LOG_CI_END="0.677839319523147" LOG_CI_START="-0.13931416196311472" LOG_EFFECT_SIZE="0.26926257878001614" MODIFIED="2015-02-18 10:47:55 +0000" MODIFIED_BY="[Empty name]" ORDER="12" SE="0.48" STUDY_ID="STD-Young-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:07:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="72" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>Pain evaluation</NAME>
<GROUP_LABEL_1>rFVIIa 270 ug/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>rFVIIa 3x90 ug/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rFVIIa 270 ug/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rFVIIa 3x90 ug/kg</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:56:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>At 1 hour</NAME>
<IV_DATA CI_END="4.796906292058114" CI_START="0.20846769545105076" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.6809612345718848" LOG_CI_START="-0.6809612345718848" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-18 10:56:56 +0000" MODIFIED_BY="[Empty name]" ORDER="15" SE="0.8" STUDY_ID="STD-Young-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:59:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>At 3 hours</NAME>
<IV_DATA CI_END="3.057418179026225" CI_START="0.12776395392629425" EFFECT_SIZE="0.6250022682827008" ESTIMABLE="YES" ESTIMATE="-0.47" LOG_CI_END="0.485354843509505" LOG_CI_START="-0.8935916564985618" LOG_EFFECT_SIZE="-0.20411840649452836" MODIFIED="2015-02-18 10:59:26 +0000" MODIFIED_BY="[Empty name]" ORDER="18" SE="0.81" STUDY_ID="STD-Young-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:00:52 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>At 6 hours</NAME>
<IV_DATA CI_END="4.608858403364752" CI_START="0.5336686215747671" EFFECT_SIZE="1.5683121854901687" ESTIMABLE="YES" ESTIMATE="0.45" LOG_CI_END="0.6635933656246341" LOG_CI_START="-0.27272833191170753" LOG_EFFECT_SIZE="0.1954325168564633" MODIFIED="2015-02-18 11:00:52 +0000" MODIFIED_BY="[Empty name]" ORDER="21" SE="0.55" STUDY_ID="STD-Young-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:01:38 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>At 9 hours</NAME>
<IV_DATA CI_END="3.7855192840394998" CI_START="0.5997855689456617" EFFECT_SIZE="1.5068177851128535" ESTIMABLE="YES" ESTIMATE="0.41" LOG_CI_END="0.5781254628913155" LOG_CI_START="-0.22200398773064908" LOG_EFFECT_SIZE="0.17806073758033322" MODIFIED="2015-02-18 11:01:38 +0000" MODIFIED_BY="[Empty name]" ORDER="24" SE="0.47" STUDY_ID="STD-Young-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:05:18 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Need for rescue medication</NAME>
<GROUP_LABEL_1>rFVIIa 270 ug/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>rFVIIa 3x90 ug/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rFVIIa 270 ug/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rFVIIa 3x90 ug/kg</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="6.831583020288116" CI_START="0.05951324290917456" EFFECT_SIZE="0.6376281516217732" ESTIMABLE="YES" ESTIMATE="-0.45" LOG_CI_END="0.8345213504335123" LOG_CI_START="-1.225386384146439" LOG_EFFECT_SIZE="-0.19543251685646337" MODIFIED="2015-02-18 11:05:18 +0000" MODIFIED_BY="[Empty name]" ORDER="27" SE="1.21" STUDY_ID="STD-Young-2008" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-03-25 15:47:34 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>rFVIIa 270 ug/kg vs APCC 75 U/kg</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:06:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Mobility evaluation</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rFVIIa 270 ug/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FEIBA 75 U/kg</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:49:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 6 hours</NAME>
<IV_DATA CI_END="8.50942241427473" CI_START="0.5060225381598016" EFFECT_SIZE="2.0750806076741224" ESTIMABLE="YES" ESTIMATE="0.73" LOG_CI_END="0.9299000829040701" LOG_CI_START="-0.2958301393253225" LOG_EFFECT_SIZE="0.3170349717893738" MODIFIED="2014-09-12 15:55:09 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SE="0.72" STUDY_ID="STD-Young-2008" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:49:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 9 hours</NAME>
<IV_DATA CI_END="4.100767161914067" CI_START="0.24385681032747092" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.6128651111146962" LOG_CI_START="-0.6128651111146963" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-18 10:49:54 +0000" MODIFIED_BY="[Empty name]" ORDER="13" SE="0.72" STUDY_ID="STD-Young-2008" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:10:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="52" TOTAL_2="52" WEIGHT="0.0" Z="0.0">
<NAME>Pain evaluation</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rFVIIa 270 ug/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APCC 75 U/kg</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:08:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 1 hour</NAME>
<IV_DATA CI_END="5.188111442339334" CI_START="0.192748365395385" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.7150092963004789" LOG_CI_START="-0.715009296300479" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-18 11:08:04 +0000" MODIFIED_BY="[Empty name]" ORDER="16" SE="0.84" STUDY_ID="STD-Young-2008" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:09:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 3 hours</NAME>
<IV_DATA CI_END="6.961224138363338" CI_START="0.05391452586378569" EFFECT_SIZE="0.6126263941844161" ESTIMABLE="YES" ESTIMATE="-0.49" LOG_CI_END="0.842685617453828" LOG_CI_START="-1.2682942097190149" LOG_EFFECT_SIZE="-0.21280429613259336" MODIFIED="2015-02-18 11:09:21 +0000" MODIFIED_BY="[Empty name]" ORDER="19" SE="1.24" STUDY_ID="STD-Young-2008" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:10:25 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 6 hours</NAME>
<IV_DATA CI_END="5.271817339606592" CI_START="0.3526161704959725" EFFECT_SIZE="1.3634251141321778" ESTIMABLE="YES" ESTIMATE="0.31" LOG_CI_END="0.7219603542082587" LOG_CI_START="-0.4526977754282424" LOG_EFFECT_SIZE="0.13463128939000807" MODIFIED="2015-02-18 11:10:25 +0000" MODIFIED_BY="[Empty name]" ORDER="22" SE="0.69" STUDY_ID="STD-Young-2008" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:10:53 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 9 hours</NAME>
<IV_DATA CI_END="2.863299952358367" CI_START="0.18415549639105827" EFFECT_SIZE="0.7261490370736909" ESTIMABLE="YES" ESTIMATE="-0.32" LOG_CI_END="0.4568668460413585" LOG_CI_START="-0.7348153144594397" LOG_EFFECT_SIZE="-0.13897423420904056" MODIFIED="2015-02-18 11:10:53 +0000" MODIFIED_BY="[Empty name]" ORDER="25" SE="0.7" STUDY_ID="STD-Young-2008" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:12:28 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Need for rescue medication</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FVIIa 270 ug/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APCC 75 U/kg</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.4763497088802526" CI_START="0.07505210838316435" EFFECT_SIZE="0.3328710836980795" ESTIMABLE="YES" ESTIMATE="-1.1" LOG_CI_END="0.16918924274971353" LOG_CI_START="-1.1246371029368676" LOG_EFFECT_SIZE="-0.4777239300935771" MODIFIED="2015-02-18 11:12:28 +0000" MODIFIED_BY="[Empty name]" ORDER="28" SE="0.76" STUDY_ID="STD-Young-2008" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-06-04 13:28:52 +0100" MODIFIED_BY="Tracey Remmington" NO="4">
<NAME>rFVIIa 90 ug/kg x 3 doses vs APCC 75 U/kg</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:15:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Mobility evaluation</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rFVIIa 3x90 ug/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APCC 75 U/kg</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:51:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 6 hours</NAME>
<IV_DATA CI_END="3.5750408045859725" CI_START="0.27971708706575465" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.5532810030896564" LOG_CI_START="-0.5532810030896563" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-18 10:51:35 +0000" MODIFIED_BY="[Empty name]" ORDER="11" SE="0.65" STUDY_ID="STD-Young-2008" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 10:51:24 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 9 hours</NAME>
<IV_DATA CI_END="1.8119016880496481" CI_START="0.14743366250372988" EFFECT_SIZE="0.5168513344916992" ESTIMABLE="YES" ESTIMATE="-0.66" LOG_CI_END="0.2581346296013616" LOG_CI_START="-0.8314033457136542" LOG_EFFECT_SIZE="-0.28663435805614623" MODIFIED="2014-09-12 16:21:44 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SE="0.64" STUDY_ID="STD-Young-2008" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:17:34 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="52" TOTAL_2="52" WEIGHT="0.0" Z="0.0">
<NAME>Pain evaluation</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rFVIIa 3x90 ug/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FEIBA 75 U/kg</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:17:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 1 hour</NAME>
<IV_DATA CI_END="6.961224138363338" CI_START="0.05391452586378569" EFFECT_SIZE="0.6126263941844161" ESTIMABLE="YES" ESTIMATE="-0.49" LOG_CI_END="0.842685617453828" LOG_CI_START="-1.2682942097190149" LOG_EFFECT_SIZE="-0.21280429613259336" MODIFIED="2015-02-18 11:17:11 +0000" MODIFIED_BY="[Empty name]" ORDER="17" SE="1.24" STUDY_ID="STD-Young-2008" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:17:23 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 3 hours</NAME>
<IV_DATA CI_END="8.98143494236412" CI_START="0.11134078311731077" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.9533457284006388" LOG_CI_START="-0.9533457284006388" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-18 11:17:23 +0000" MODIFIED_BY="[Empty name]" ORDER="20" SE="1.12" STUDY_ID="STD-Young-2008" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:17:28 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 6 hours</NAME>
<IV_DATA CI_END="2.092544002117902" CI_START="0.2519863016067362" EFFECT_SIZE="0.7261490370736909" ESTIMABLE="YES" ESTIMATE="-0.32" LOG_CI_END="0.3206745991269816" LOG_CI_START="-0.5986230675450629" LOG_EFFECT_SIZE="-0.13897423420904056" MODIFIED="2015-02-18 11:17:28 +0000" MODIFIED_BY="[Empty name]" ORDER="23" SE="0.54" STUDY_ID="STD-Young-2008" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:17:34 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 9 hours</NAME>
<IV_DATA CI_END="1.7781580596285174" CI_START="0.1627438102996913" EFFECT_SIZE="0.5379444375946745" ESTIMABLE="YES" ESTIMATE="-0.62" LOG_CI_END="0.24997036258104594" LOG_CI_START="-0.7884955201410783" LOG_EFFECT_SIZE="-0.26926257878001614" MODIFIED="2015-02-18 11:17:34 +0000" MODIFIED_BY="[Empty name]" ORDER="26" SE="0.61" STUDY_ID="STD-Young-2008" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-18 11:17:56 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Need for rescue medication</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rFVIIa 3x90 ug/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FEIBA 75 U/kg</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.6685680196305614" CI_START="0.04027735875857777" EFFECT_SIZE="0.2592402606458915" ESTIMABLE="YES" ESTIMATE="-1.35" LOG_CI_END="0.22234391548472313" LOG_CI_START="-1.3949390166235032" LOG_EFFECT_SIZE="-0.5862975505693899" MODIFIED="2015-02-18 11:17:56 +0000" MODIFIED_BY="[Empty name]" ORDER="29" SE="0.95" STUDY_ID="STD-Young-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-09-28 09:29:53 +0100" MODIFIED_BY="Davide Matino"/>
<FEEDBACK MODIFIED="2009-09-28 09:29:53 +0100" MODIFIED_BY="Davide Matino"/>
<APPENDICES MODIFIED="2009-09-28 09:29:53 +0100" MODIFIED_BY="Davide Matino"/>
<EXTENSIONS MODIFIED="2009-09-28 09:29:53 +0100" MODIFIED_BY="Davide Matino"/>
</COCHRANE_REVIEW>